<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">102232</article-id><article-id pub-id-type="doi">10.7554/eLife.102232</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.102232.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Temporal dynamics of viral fitness and the adaptive immune response in HCV infection</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Walker</surname><given-names>Melanie Rose</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9731-9880</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Leung</surname><given-names>Preston</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Keoshkerian</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Pirozyan</surname><given-names>Mehdi R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Lloyd</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Luciani</surname><given-names>Fabio</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0666-6324</contrib-id><email>luciani@unsw.edu.au</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Bull</surname><given-names>Rowena A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Viral Immunology Systems Program, The Kirby Institute</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r8z3t63</institution-id><institution>School of Biomedical Sciences, Faculty of Medicine, The University of New South Wales</institution></institution-wrap><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Delgui</surname><given-names>Laura Ruth</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cqe8w59</institution-id><institution>Consejo Nacional de Investigaciones Científicas y Técnicas</institution></institution-wrap><country>Argentina</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Diamond</surname><given-names>Betty</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dnene97</institution-id><institution>The Feinstein Institute for Medical Research</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>29</day><month>08</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP102232</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-09-07"><day>07</day><month>09</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-09-13"><day>13</day><month>09</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.09.07.611784"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-11-13"><day>13</day><month>11</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.102232.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-04-10"><day>10</day><month>04</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.102232.2"/></event></pub-history><permissions><copyright-statement>© 2024, Walker, Leung et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Walker, Leung et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-102232-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-102232-figures-v1.pdf"/><abstract><p>Numerous studies have shown that viral variants that elude the host immune response may incur a fitness expense, diminishing the survival of the viral strain within the host, and the capacity of the variant to survive future transmission events. This definition can be divided into intrinsic fitness—fitness without immune pressure—and effective fitness, which includes immune influence. Co-occurring mutations outside immune-targeted epitope regions may also affect variant survival (epistasis). Analysis of viral fitness and epistasis over the non-structural protein regions is lacking for hepatitis C virus (HCV). Using a rare cohort of subjects recently infected with HCV, we build on prior work by integrating mathematical modeling and experimental data to examine the interplay between transmitted/founder (T/F) viruses, immune responses, fitness, and co-occurring mutations. We show that viral fitness declines during the first 90 days post-infection (DPI), associated with the magnitude of CD8 +T cell responses and early diversification. Fitness then rebounds in a complex pattern marked by co-occurring mutations. Finally, we demonstrate that an early, strong CD8 +T cell response in the absence of neutralizing antibodies (nAbs) exerts strong selective pressure, allowing escape and chronic infection. These insights support HCV vaccine strategies that elicit broad T and B cell immunity.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>hepatitis C virus</kwd><kwd>fitness</kwd><kwd>immunity</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>1128416</award-id><principal-award-recipient><name><surname>Luciani</surname><given-names>Fabio</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>1041897</award-id><principal-award-recipient><name><surname>Lloyd</surname><given-names>Andrew</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>1084706</award-id><principal-award-recipient><name><surname>Bull</surname><given-names>Rowena A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Early immune pressure and co-occurring mutations drive changes in hepatitis C virus fitness and evolution, revealing key dynamics in the establishment of chronic infection.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Hepatitis C virus (HCV) is a major cause of chronic liver disease globally (<xref ref-type="bibr" rid="bib23">Lanini et al., 2016</xref>). Following acute infection, approximately 75% of people fail to clear the virus, resulting in chronic hepatitis with progressive fibrosis and ultimately cirrhosis, liver failure, and an increased risk of hepatocellular carcinoma (<xref ref-type="bibr" rid="bib42">Seeff, 2002</xref>; <xref ref-type="bibr" rid="bib24">Lavanchy, 2009</xref>; <xref ref-type="bibr" rid="bib29">Micallef et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Santantonio et al., 2008</xref>). Despite the arrival of direct-acting antiviral agents (DAA) with remarkable efficacy, the unresolved financial and health service challenges in ensuring universal DAA access to those infected globally, and likelihood of reinfection in high-risk populations, necessitate a prophylactic vaccine as an essential component for the WHO goal of global elimination of HCV infection as a public health threat (<xref ref-type="bibr" rid="bib15">Fuerst et al., 2017</xref>).</p><p>Due to a high mutation rate during replication, the HCV genome is highly diverse, being classified into eight major genotypes (genotypes 1–8), and 86 subtypes (labeled alphabetically [a, b, c, etc.]) (<xref ref-type="bibr" rid="bib43">Smith et al., 2014</xref>; <xref ref-type="bibr" rid="bib19">Hedskog et al., 2019</xref>). HCV also exists within each infected host as a diverse, rapidly evolving population termed a quasispecies. Nevertheless, transmission of HCV is associated with a strong genetic bottleneck with as few as 1–3 transmitted/founder (T/F) viruses commonly establishing infection in the new host, despite hundreds of individual variants found in the source (<xref ref-type="bibr" rid="bib27">Li et al., 2016</xref>; <xref ref-type="bibr" rid="bib5">Bull et al., 2011</xref>). This is followed by a second genetic bottleneck at ~100 days post-infection (DPI), where T/F viruses become undetectable. At this stage, either an existing variant that was occurring in low frequency outside detection range or an existing variant with novel mutations generated following immune selection is observed in those who progress to chronic infection. These variants carry mutations within epitopes targeted by B cell and CD8 +T cells (<xref ref-type="bibr" rid="bib5">Bull et al., 2011</xref>). Indeed, clearance of HCV has been associated with an early onset of T/F-specific neutralizing antibodies (nAbs) (<xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>; <xref ref-type="bibr" rid="bib12">Dowd et al., 2009</xref>; <xref ref-type="bibr" rid="bib25">Lavillette et al., 2005</xref>; <xref ref-type="bibr" rid="bib32">Osburn et al., 2014</xref>), while early and strong CD8 +T cell responses against the T/F virus have been associated with the generation of immune escape mutations found within MHC-I restricted epitopes which lead to the progression of chronic infection (<xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>).</p><p>Numerous virological studies have shown that viral variants that elude the host immune response might incur a fitness expense, diminishing the survival of the viral strain and reducing the capacity of the variant to survive future transmission events as the variants mutate away from the T/F virus (<xref ref-type="bibr" rid="bib40">Sanjuán et al., 2004</xref>; <xref ref-type="bibr" rid="bib45">Venner et al., 2016</xref>). This generic definition of fitness can be further divided into intrinsic fitness (also referred to as replicative fitness), where the fitness of sequence composition of the variant is estimated without the influence of host immune pressure. On the other hand, effective fitness (from here on referred to as viral fitness) considers fundamental intrinsic fitness with host immune pressure acting as a selective force to direct mutational landscape (<xref ref-type="bibr" rid="bib18">Hart and Ferguson, 2015</xref>), which subsequently influences future transmission events as it dictates which subvariants remain in the quasispecies. In HCV, the structural envelope proteins, E1 and E2, which are predominantly targeted by B cell responses including neutralizing antibodies (nAbs), have been found to collectively mediate viral fitness (<xref ref-type="bibr" rid="bib54">Zhang et al., 2023</xref>). This interdependence suggests that mutations in the E1 protein could potentially compensate for fitness deficits, thereby facilitating the virus' ability to evade antibodies that specifically target the E2 protein (<xref ref-type="bibr" rid="bib54">Zhang et al., 2023</xref>). Furthermore, comparative analyses of E2 fitness in genotype 1 a and genotype 1b sequences found that subtype 1b viruses have a higher probability to evade immune responses (<xref ref-type="bibr" rid="bib36">Quadeer et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Zhang et al., 2022</xref>). By contrast, a comprehensive analysis of the non-structural protein regions (NS1, NS2, NS3, NS4A, NS4B, NS5A, NS5B) in mediating viral fitness is lacking. For the scope of this study, a fitness model developed for HIV (<xref ref-type="bibr" rid="bib13">Ferguson et al., 2013</xref>; <xref ref-type="bibr" rid="bib3">Barton et al., 2016</xref>) and modified for HCV (<xref ref-type="bibr" rid="bib18">Hart and Ferguson, 2015</xref>) was used to estimate the fitness landscape of HCV subtypes. Barton et al.’s approach to understand HIV mutational landscape resulting in immune escape had two fundamental points: (1) replicative fitness depends on the virus sequence and the requirement to consider the effect of co-occurring mutations, and (2) evolutionary dynamics (e.g. host immune pressure) (<xref ref-type="bibr" rid="bib3">Barton et al., 2016</xref>). Together they pave the way to predict the mutational space in which viral strains can change given the unique immune pressure exerted by individuals infected with HIV. This model fits well with the pathology of HCV infection. For instance, HIV and HCV are both RNA viruses with rapid rates of mutation. Additionally, like HIV, chronic infection is an outcome for HCV-infected individuals; however, unlike HIV, there is a 25% probability that individuals infected with HCV will naturally clear the virus. Previously published studies (<xref ref-type="bibr" rid="bib21">Keele et al., 2008</xref>) have shown that HIV also goes through a genetic bottleneck which results in the T/F virus losing dominance and being replaced by a chronic subtype, identified by the immune escape mutations. The concepts in Barton’s model and its functionality to assess fitness based on the complex interaction between viral sequence composition and host immune response are also applicable to early HCV infection. For generating the viral fitness models, sequences in clinical databases were used to represent the circulating viral variants with the assumption that commonly observed viral variants denoted higher fitness. This model was then used to infer the initial fitness landscape by providing the T/F virus and producing a fitness value. The fitness of the subsequent variants was then described as the relative fitness in comparison to the T/F virus, over the course of an infection.</p><p>Mutations that can incur a fitness expense can typically be alleviated or compensated by other mutations, making certain combinations of mutations beneficial (<xref ref-type="bibr" rid="bib9">Campo et al., 2008</xref>). These co-occurring mutations can arise outside of the epitope regions and facilitate their compensatory effects, thus increasing the likelihood of survival of the variant (<xref ref-type="bibr" rid="bib31">Oniangue-Ndza et al., 2011</xref>). This phenomenon is called positive epistasis. However, epistasis may also be negative if a combination of mutations provides a smaller fitness gain than anticipated based on the additive effects of the individual mutations. Nevertheless, epistatic interactions in HCV have not been studied over acute and chronic phase sequences to infer HCV evolution over the course of the infection. Understanding viral fitness and epistatic interactions in HCV is critical in anticipating future substitutions that are antigenically significant, thus aiding in not only mapping the potential landscape of evolution, but also an improved strategic approach for the selection of potent vaccine strains.</p><p>Previously, we longitudinally deep sequenced HCV in 14 individuals who were recently infected with HCV to identify the T/F virus and the evolving quasispecies during the infection (<xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>). We identified Human Leucocyte Antigen class I (HLA-I) epitopes from the T/F viruses and the mutated variants. Experimental testing using IFN-γ ELISpot revealed that a strong CD8 +T cell response was linked to rapid immune evasion (<xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>). Here, we build upon our prior investigations by integrating mathematical models and experimental data to examine the interplay between evolving T/F viruses, the adaptive immune response, viral fitness, and co-occurring mutations.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Prediction, generation, and validation of HLA class I-restricted epitopes</title><p>A total of 14 subjects with primary HCV infection followed from pre-seroconversion until infection outcome were included in this study (<xref ref-type="table" rid="table1">Table 1</xref>). The first available viremic sample was collected at a median of 68 days post-infection (DPI) (range 2–337 DPI). Of the 14 subjects included in this study, 8 subjects naturally cleared the infection (termed here clearers) and 6 subjects progressed to chronic infection (termed here chronic progressors). The median time to natural clearance was 163 DPI (range 69–357). Next-generation sequencing (NGS) data were available for eight viremic time points from these subjects to study HCV RNA populations in depth. The T/F viruses were estimated from the distribution of variants at the earliest sampling time point as previously described (<xref ref-type="bibr" rid="bib5">Bull et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>; <xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>). Thirteen of the 14 subjects had a single T/F virus, with only subject 300023 having two T/F viruses identified, as previously published (<xref ref-type="bibr" rid="bib5">Bull et al., 2011</xref>; <xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>). T/F genomes were utilized to predict HLA-I epitopes from the T/F viruses and the mutated variants (<xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>). These epitopes were tested and validated for IFN-γ ELISPOT (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Subject characteristics and time point analysis.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Subject ID<sup><xref ref-type="table-fn" rid="table1fn1">*</xref></sup></th><th align="left" valign="bottom">Age</th><th align="left" valign="bottom">Sex</th><th align="left" valign="bottom">Disease outcome</th><th align="left" valign="bottom">GT<sup><xref ref-type="table-fn" rid="table1fn2">†</xref></sup></th><th align="left" valign="bottom" colspan="2">HLA-A</th><th align="left" valign="bottom" colspan="2">HLA-B</th><th align="left" valign="bottom">First sampling point (DPI<xref ref-type="table-fn" rid="table1fn3"><sup>‡</sup></xref>)</th><th align="left" valign="bottom">Time to clearance</th><th align="left" valign="bottom">Initial viral load</th><th align="left" valign="bottom">No. samples sequenced<sup><xref ref-type="table-fn" rid="table1fn4">§</xref></sup></th><th align="left" valign="bottom">No. T/F<sup><xref ref-type="table-fn" rid="table1fn5">¶</xref></sup> viruses</th></tr></thead><tbody><tr><td align="left" valign="bottom">300023</td><td align="left" valign="bottom">22</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">Chronic</td><td align="left" valign="bottom">1 a</td><td align="left" valign="bottom">02:01</td><td align="left" valign="bottom">02:01</td><td align="left" valign="bottom">44:02:00</td><td align="left" valign="bottom">57:01:00</td><td align="left" valign="bottom">36</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">19,234,348</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">2</td></tr><tr><td align="left" valign="bottom">300240</td><td align="left" valign="bottom">21</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">Chronic</td><td align="left" valign="bottom">3 a</td><td align="left" valign="bottom">02:01</td><td align="left" valign="bottom">02:01</td><td align="left" valign="bottom">15:01</td><td align="left" valign="bottom">57:01:00</td><td align="left" valign="bottom">44</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">54,887</td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">300256</td><td align="left" valign="bottom">31</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">Chronic</td><td align="left" valign="bottom">1 a</td><td align="left" valign="bottom">03:01</td><td align="left" valign="bottom">24:02:00</td><td align="left" valign="bottom">07:02</td><td align="left" valign="bottom">35:01:00</td><td align="left" valign="bottom">44</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">34,149,824</td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">HOKD0485FX</td><td align="left" valign="bottom">26</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">Chronic</td><td align="left" valign="bottom">1b</td><td align="left" valign="bottom">01:01</td><td align="left" valign="bottom">30:01:00</td><td align="left" valign="bottom">08:01</td><td align="left" valign="bottom">13:02</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">733,849</td><td align="left" valign="bottom">8</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">THDS1086MX</td><td align="left" valign="bottom">25</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">Chronic</td><td align="left" valign="bottom">1 a</td><td align="left" valign="bottom">02:01</td><td align="left" valign="bottom">32:01:00</td><td align="left" valign="bottom">14:02</td><td align="left" valign="bottom">27:05:00</td><td align="left" valign="bottom">16</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">235,662</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">THGS0684MX</td><td align="left" valign="bottom">28</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">Chronic</td><td align="left" valign="bottom">1 a</td><td align="left" valign="bottom">02:01</td><td align="left" valign="bottom">32:01:00</td><td align="left" valign="bottom">27:02:00</td><td align="left" valign="bottom">40:01:00</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">140,200</td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">300360</td><td align="left" valign="bottom">29</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">Clearer</td><td align="left" valign="bottom">3 a</td><td align="left" valign="bottom">68:02:00</td><td align="left" valign="bottom">32:01:00</td><td align="left" valign="bottom">14:02</td><td align="left" valign="bottom">40:01:00</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">178</td><td align="left" valign="bottom">5,648,631</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">300277</td><td align="left" valign="bottom">25</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">Clearer</td><td align="left" valign="bottom">3 a</td><td align="left" valign="bottom">02:01</td><td align="left" valign="bottom">11:01</td><td align="left" valign="bottom">44:02:00</td><td align="left" valign="bottom">44:02:00</td><td align="left" valign="bottom">39</td><td align="left" valign="bottom">69</td><td align="left" valign="bottom">5,482,503</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">MCRL0786FX</td><td align="left" valign="bottom">25</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">Clearer</td><td align="left" valign="bottom">1 a</td><td align="left" valign="bottom">01:01</td><td align="left" valign="bottom">29:02:00</td><td align="left" valign="bottom">44:02:00</td><td align="left" valign="bottom">44:02:00</td><td align="left" valign="bottom">80</td><td align="left" valign="bottom">115</td><td align="left" valign="bottom">1846</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">400087</td><td align="left" valign="bottom">32</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">Clearer</td><td align="left" valign="bottom">1b</td><td align="left" valign="bottom">24:02:00</td><td align="left" valign="bottom">30:04:00</td><td align="left" valign="bottom">14:02</td><td align="left" valign="bottom">15:06</td><td align="left" valign="bottom">45</td><td align="left" valign="bottom">139</td><td align="left" valign="bottom">13,118,082</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">300364</td><td align="left" valign="bottom">29</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">Clearer</td><td align="left" valign="bottom">1 a</td><td align="left" valign="bottom">01:01</td><td align="left" valign="bottom">03:01</td><td align="left" valign="bottom">07:02</td><td align="left" valign="bottom">57:01:00</td><td align="left" valign="bottom">337</td><td align="left" valign="bottom">352</td><td align="left" valign="bottom">1932</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">300231</td><td align="left" valign="bottom">22</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">Clearer</td><td align="left" valign="bottom">3 a</td><td align="left" valign="bottom">01:01</td><td align="left" valign="bottom">01:01</td><td align="left" valign="bottom">07:02</td><td align="left" valign="bottom">57:01:00</td><td align="left" valign="bottom">6</td><td align="left" valign="bottom">148</td><td align="left" valign="bottom">2,242,163</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">300089</td><td align="left" valign="bottom">26</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">Clearer</td><td align="left" valign="bottom">1b</td><td align="left" valign="bottom">01:01</td><td align="left" valign="bottom">30:01:00</td><td align="left" valign="bottom">07:02</td><td align="left" valign="bottom">57:01:00</td><td align="left" valign="bottom">181</td><td align="left" valign="bottom">357</td><td align="left" valign="bottom">70,737</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">300164</td><td align="left" valign="bottom">22</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">Clearer</td><td align="left" valign="bottom">3 a</td><td align="left" valign="bottom">24:02:00</td><td align="left" valign="bottom">32:01:00</td><td align="left" valign="bottom">07:02</td><td align="left" valign="bottom">40:01:00</td><td align="left" valign="bottom">71</td><td align="left" valign="bottom">204</td><td align="left" valign="bottom">684,028</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><label>*</label><p>Identification.</p></fn><fn id="table1fn2"><label>†</label><p>Genotype.</p></fn><fn id="table1fn3"><label> ‡</label><p>Days post infection.</p></fn><fn id="table1fn4"><label> §</label><p>Next generation sequencing.</p></fn><fn id="table1fn5"><label> ¶</label><p>Transmitted/Founder.</p></fn></table-wrap-foot></table-wrap><p>To examine the role of CD8 +T cell responses in driving viral evolution, longitudinal deep sequenced data was analyzed for fixation events as previously described (<xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>). For those subjects who ultimately spontaneously cleared HCV infection, there were no non-synonymous fixation mutations (defined as having frequency of occurrence greater than or equal to 70% in the sequencing data) occurring within epitope regions (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Therefore, subjects who cleared infection were not included for further analysis of viral fitness and immune escape throughout this manuscript. From the six subjects who developed chronic infection, non-synonymous fixation mutations occurring within epitope regions were observed and peptide epitopes were selected (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). A total of 494 out of 10945 (4.51%) potential epitopes across the six chronic subjects (45–100 epitopes per subject) were selected and tested for IFN-γ ELISPOT (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Of those selected for testing, 30 (6.68%) epitopes induced positive responses in the IFN-γ ELISPOT, and of these, 14 epitopes showed evidence of escape (as indicated by reduced recognition in the IFN-γ ELISPOT assay; <xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>IFN-γ response and the relationship between viral diversity and the rate of immune escape in subjects chronically infected with HCV.</title><p>IFN-γ ELISpot values (SFU/million, right y-axis) and viral load (IU/mL, left y-axis) measured in subjects (<bold>A</bold>) 300256, (<bold>B</bold>) THDS1086MX and (<bold>C</bold>). THGS0684MX for epitope-specific CD8 +T cell responses (see key). Subjects HOKD0485FX, 300023 and 300240 have been shown previously (<xref ref-type="bibr" rid="bib5">Bull et al., 2011</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>). Escape variants are shown with a clear symbol of the original epitope found in the transmitted/founder (see key). IFN-γ ELISpot values were generated from multiple biological samples. Peptides were pooled and tested in technical duplicate; positive responses were confirmed by testing the individual peptide in a follow-up IFN-γ ELISpot assay. (<bold>D</bold>) Plot of average Shannon entropy (SE) against the rate of escape for each epitope in each protein region per subject. Plots of average SE against average IFN-γ ELISPOT response at &gt;90 DPI (purple) (<bold>E</bold>) and &lt;90 DPI (green) (<bold>F</bold>) are also shown. p-Values (P) and Pearson’s correlation coefficient (R) are shown in the top left corner of each panel.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Source data of IFN-γ response, viral diversity and the rate of immune escape in subjects chronically infected with HCV.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102232-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102232-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Magnitude of CD8 +T cell responses associated with escape.</title><p>CD8 +T cell responses were tested by IFN-γ ELISPOT assays measuring spot-forming unit per million cells (SFU/million cell) of epitopes (vertical axis) across three populations. The horizontal axis from left to right shows the population of epitopes that undergo fixation events in subjects who became chronically infected by HCV (Ch), epitopes that had no mutations, and epitopes from subjects that spontaneously cleared HCV infection (Cl). Statistical comparisons are Mann-Whitney tests. Scatter plots represent means and standard deviation.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102232-fig1-figsupp1-v1.tif"/></fig></fig-group><p>The location of these 14 epitopes associated with escape was mostly within the non-structural regions of the HCV genome, with 7 (50%) epitopes identified in the NS3 region, 3 (21.4%) in NS5B, and 2 (14.3%) in NS2. One (7%) epitope was identified in the Core region and one (7%) in E2, which were both found in subject 300256 (<xref ref-type="table" rid="table2">Table 2</xref>). Single fixation events were observed in the majority of these epitopes, with the exception of two epitopes (in subjects HOKD0485FX and 300256) where two fixation events occurred (<xref ref-type="table" rid="table2">Table 2</xref>).</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Epitopes and escape rate of epitopes from chronic progressors with fixation events where positive IFN-γ ELISPOT response was detected on the T/F virus.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Subject ID</th><th align="left" valign="bottom">GT</th><th align="left" valign="bottom">Epitope (MT)<sup><xref ref-type="table-fn" rid="table2fn1">*</xref>,<xref ref-type="table-fn" rid="table2fn2">†</xref></sup></th><th align="left" valign="bottom">Epitope (WT)<sup><xref ref-type="table-fn" rid="table2fn2">†</xref></sup></th><th align="left" valign="bottom">Start aa</th><th align="left" valign="bottom">End aa</th><th align="left" valign="bottom">Region</th><th align="left" valign="bottom">ELISPOT<sup><xref ref-type="table-fn" rid="table2fn3">‡</xref></sup></th><th align="left" valign="bottom">DPI<sup><xref ref-type="table-fn" rid="table2fn4">§</xref></sup></th><th align="left" valign="bottom">Matching Subject Allele</th><th align="left" valign="bottom">Predicted Rank (WT)</th><th align="left" valign="bottom">Rank Change</th><th align="left" valign="bottom">Epsilon Estimate<sup><xref ref-type="table-fn" rid="table2fn5">¶</xref></sup></th><th align="left" valign="bottom">p-Value</th><th align="left" valign="bottom">Fitness Estimated</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="2">300023</td><td align="left" valign="bottom" rowspan="2">1a</td><td align="left" valign="bottom">RAEA<styled-content style="color: #D50000;">H</styled-content>LHAW</td><td align="left" valign="bottom">RAEA<styled-content style="color: #D50000;">Q</styled-content>LHAW</td><td align="left" valign="bottom">852</td><td align="left" valign="bottom">860</td><td align="left" valign="bottom">NS2</td><td align="left" valign="bottom">91</td><td align="left" valign="bottom">60</td><td align="left" valign="bottom">HLA-B*57:01</td><td align="left" valign="bottom">0.3</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0.0625</td><td align="left" valign="bottom">0.0001</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><styled-content style="color: #D50000;">N</styled-content>SKRTPMGF</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">K</styled-content>SKRTPMGF</td><td align="left" valign="bottom">2629</td><td align="left" valign="bottom">2637</td><td align="left" valign="bottom">NS5B</td><td align="left" valign="bottom">484</td><td align="left" valign="bottom">60</td><td align="left" valign="bottom">HLA-B*57:01</td><td align="left" valign="bottom">0.45</td><td align="left" valign="bottom">–2.2</td><td align="left" valign="bottom">0.1243</td><td align="left" valign="bottom">0.0036</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom" rowspan="2">300240</td><td align="left" valign="bottom" rowspan="2">3a</td><td align="left" valign="bottom">RAQA<styled-content style="color: #D50000;">L</styled-content>PPSW</td><td align="left" valign="bottom">RAQA<styled-content style="color: #D50000;">P</styled-content>PPSW</td><td align="left" valign="bottom">1602</td><td align="left" valign="bottom">1610</td><td align="left" valign="bottom">NS3</td><td align="left" valign="bottom">55</td><td align="left" valign="bottom">44</td><td align="left" valign="bottom">HLA-B*57:01</td><td align="left" valign="bottom">0.2</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0.1025</td><td align="left" valign="bottom">0.0236</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom">RLGPVQNE<styled-content style="color: #D50000;">I</styled-content></td><td align="left" valign="bottom">RLGPVQNE<styled-content style="color: #D50000;">V</styled-content></td><td align="left" valign="bottom">1633</td><td align="left" valign="bottom">1641</td><td align="left" valign="bottom">NS3</td><td align="left" valign="bottom">300</td><td align="left" valign="bottom">71</td><td align="left" valign="bottom">HLA-A*02:01</td><td align="left" valign="bottom">1.6</td><td align="left" valign="bottom">–2.1</td><td align="left" valign="bottom">0.0303</td><td align="left" valign="bottom">0.0001</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom" rowspan="3">300256</td><td align="left" valign="bottom" rowspan="3">1a</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">D</styled-content>YPYRLWHY</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">H</styled-content>YPYRLWHY</td><td align="left" valign="bottom">610</td><td align="left" valign="bottom">618</td><td align="left" valign="bottom">E2</td><td align="left" valign="bottom">750</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">HLA-A*24:02</td><td align="left" valign="bottom">1.45</td><td align="left" valign="bottom">–0.5</td><td align="left" valign="bottom">0.4813</td><td align="left" valign="bottom">0.0242</td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">GP<styled-content style="color: #D50000;">KM</styled-content>GVRAT</td><td align="left" valign="bottom">GP<styled-content style="color: #D50000;">RL</styled-content>GVRAT</td><td align="left" valign="bottom">41</td><td align="left" valign="bottom">49</td><td align="left" valign="bottom">Core</td><td align="left" valign="bottom">25</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">HLA-B*07:02</td><td align="left" valign="bottom">0.4</td><td align="left" valign="bottom">–1.4</td><td align="left" valign="bottom">0.0532</td><td align="left" valign="bottom">0.0413</td><td align="left" valign="bottom">N/A</td></tr><tr><td align="left" valign="bottom">HP<styled-content style="color: #D50000;">S</styled-content>IEEVAL</td><td align="left" valign="bottom">HP<styled-content style="color: #D50000;">N</styled-content>IEEVAL</td><td align="left" valign="bottom">1359</td><td align="left" valign="bottom">1367</td><td align="left" valign="bottom">NS3</td><td align="left" valign="bottom">150</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">HLA-B*35:01</td><td align="left" valign="bottom">0.5</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0.0565</td><td align="left" valign="bottom">0.0001</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom">HOKD0485FX</td><td align="left" valign="bottom">1b</td><td align="left" valign="bottom">HS<styled-content style="color: #D50000;">RR</styled-content>KCDEL</td><td align="left" valign="bottom">HSK<styled-content style="color: #D50000;">KK</styled-content>CDEL</td><td align="left" valign="bottom">1395</td><td align="left" valign="bottom">1403</td><td align="left" valign="bottom">NS3</td><td align="left" valign="bottom">55</td><td align="left" valign="bottom">79</td><td align="left" valign="bottom">HLA-B*08:01</td><td align="left" valign="bottom">3.3</td><td align="left" valign="bottom">0.5</td><td align="left" valign="bottom">0.2685</td><td align="left" valign="bottom">0.972</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom" rowspan="3">THDS1086MX</td><td align="left" valign="bottom" rowspan="3">1a</td><td align="left" valign="bottom">KLVAMG<styled-content style="color: #D50000;">L</styled-content>NAV</td><td align="left" valign="bottom">KLVAMG<styled-content style="color: #D50000;">I</styled-content>NAV</td><td align="left" valign="bottom">1406</td><td align="left" valign="bottom">1415</td><td align="left" valign="bottom">NS3</td><td align="left" valign="bottom">85</td><td align="left" valign="bottom">72</td><td align="left" valign="bottom">HLA-A*02:01</td><td align="left" valign="bottom">0.75</td><td align="left" valign="bottom">0.5</td><td align="left" valign="bottom">0.5098</td><td align="left" valign="bottom">0.0005</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom">TLSPYYKR<styled-content style="color: #D50000;">H</styled-content>I</td><td align="left" valign="bottom">TLSPYYKR<styled-content style="color: #D50000;">Y</styled-content>I</td><td align="left" valign="bottom">830</td><td align="left" valign="bottom">839</td><td align="left" valign="bottom">NS2</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">72</td><td align="left" valign="bottom">HLA-A*02:01</td><td align="left" valign="bottom">3.35</td><td align="left" valign="bottom">–6.05</td><td align="left" valign="bottom">0.0689</td><td align="left" valign="bottom">0.0003</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><styled-content style="color: #D50000;">V</styled-content>RMVMMTHF</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">A</styled-content>RMVMMTHF</td><td align="left" valign="bottom">2841</td><td align="left" valign="bottom">2849</td><td align="left" valign="bottom">NS5B</td><td align="left" valign="bottom">25</td><td align="left" valign="bottom">72</td><td align="left" valign="bottom">HLA-B*27:05</td><td align="left" valign="bottom">0.2</td><td align="left" valign="bottom">–0.1</td><td align="left" valign="bottom">0.2582</td><td align="left" valign="bottom">0.0034</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom" rowspan="3">THGS0684MX</td><td align="left" valign="bottom" rowspan="3">1a</td><td align="left" valign="bottom">TSILGIGT<styled-content style="color: #D50000;">V</styled-content></td><td align="left" valign="bottom">TSILGIGT<styled-content style="color: #D50000;">A</styled-content></td><td align="left" valign="bottom">1324</td><td align="left" valign="bottom">1332</td><td align="left" valign="bottom">NS3</td><td align="left" valign="bottom">230</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">HLA-A*02:01</td><td align="left" valign="bottom">32</td><td align="left" valign="bottom">17</td><td align="left" valign="bottom">0.2861</td><td align="left" valign="bottom">0.0145</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom">SILGIGT<styled-content style="color: #D50000;">V</styled-content>L</td><td align="left" valign="bottom">SILGIGT<styled-content style="color: #D50000;">A</styled-content>L</td><td align="left" valign="bottom">1325</td><td align="left" valign="bottom">1333</td><td align="left" valign="bottom">NS3</td><td align="left" valign="bottom">405</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">HLA-A*02:01</td><td align="left" valign="bottom">5.6</td><td align="left" valign="bottom">–1.2</td><td align="left" valign="bottom">0.2861</td><td align="left" valign="bottom">0.0145</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom">AWETAR<styled-content style="color: #D50000;">Y</styled-content>TPV</td><td align="left" valign="bottom">AWETAR<styled-content style="color: #D50000;">H</styled-content>TPV</td><td align="left" valign="bottom">2816</td><td align="left" valign="bottom">2825</td><td align="left" valign="bottom">NS5B</td><td align="left" valign="bottom">50</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">HLA-A*02:01</td><td align="left" valign="bottom">36.5</td><td align="left" valign="bottom">3.5</td><td align="left" valign="bottom">0.1082</td><td align="left" valign="bottom">0.0484</td><td align="left" valign="bottom">Yes</td></tr></tbody></table><table-wrap-foot><fn id="table2fn1"><label>*</label><p>Final most dominant escape variant is shown (i.e. frequency of occurrence &gt;70%).</p></fn><fn id="table2fn2"><label>†</label><p>Red shows the positions which undergo amino acid change.</p></fn><fn id="table2fn3"><label> ‡</label><p> IFN-γ ELISPOT test of autologous PBMC measured in SFU per million PBMC against wild type epitope at earliest sample time point with a positive assay (shown in DPI column). WT - Wild Type and MT - Mutant Mutant epitopes are sourced from the final available deep sequenced data point.</p></fn><fn id="table2fn4"><label> §</label><p>Days post infection.</p></fn><fn id="table2fn5"><label> ¶</label><p>The epsilon estimate is the rate of escape given in per day.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-2"><title>CD8+ T-cell responses contribute to the diversification of the viral population</title><p>In these same subjects, we previously found that high magnitude of IFN-γ responses were associated with rapid viral immune escape (<xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>). Additionally, the interaction between immunodominance, entropy, and escape rate in acute HIV infection has been described, where immunodominance during acute infection was the most significant factor influencing CD8 +T cell pressure, with higher immunodominance linked to faster escape (<xref ref-type="bibr" rid="bib28">Liu et al., 2013</xref>). In contrast, lower epitope entropy slowed escape, and together, immunodominance and entropy explained half of the variability in escape timing (<xref ref-type="bibr" rid="bib28">Liu et al., 2013</xref>). To expand on these findings and determine whether viral diversity correlated with immune escape, Shannon entropy (SE) was calculated (<xref ref-type="bibr" rid="bib5">Bull et al., 2011</xref>) across each protein region at the preceding time points to those identified to have fixation in T-cell targeted epitopes, and tested (<xref ref-type="table" rid="table2">Table 2</xref>) against the rate of escape (ϵ) estimated from the distribution of viral mutations in the NGS data. A significant positive correlation was found between SE and the rate of escape (Pearson’s correlation = 0.73, p-value = 0.01), indicating the higher diversity was associated with the occurrence of immune escape (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p><p>To determine whether CD8 +T cell pressure was driving genomic diversification before and after the genetic bottleneck, the average IFN-γ ELISPOT response within each subject was calculated across multiple epitopes in the same protein region at each time point. This data was then correlated with global SE at two periods,&lt;90 DPI and &gt;90 DPI. At &gt;90 DPI a significant positive correlation was found (Pearson’s correlation = 0.83, p-value = 0.01, <xref ref-type="fig" rid="fig1">Figure 1E</xref>), indicating that a stronger IFN-γ ELISPOT response was associated with higher diversity following the second genetic bottleneck. Interestingly, this relationship was not evident when examining time points at &lt;90 DPI (Pearson’s correlation = 0.33, p-value = 0.23, <xref ref-type="fig" rid="fig1">Figure 1F</xref>). When considering both pre- and post-90 DPI periods, diversity appeared to be influenced by distinct selective pressures where the CD8 +T cell response plays a significant role in shaping viral population diversity, along with the emergence of epitope escape variants at &gt;90 DPI.</p></sec><sec id="s2-3"><title>Viral fitness decreases during the first 90 DPI and is associated with the magnitude of CD8+ T-cell responses and the initial level of diversification</title><p>To understand how CD8 +T cell responses influence the evolution of viral fitness in the acute phase of infection and how the viral population adapts to the host, a quantitative analysis of viral fitness in viral haplotypes on longitudinal samples was performed. We utilized a fitness model initially developed for HIV (<xref ref-type="bibr" rid="bib3">Barton et al., 2016</xref>) and adapted for HCV to estimate the fitness landscape of various HCV subtypes [24]. This model was then applied to infer the initial fitness landscape by providing the T/F virus, which generated a fitness value. The fitness of subsequent variants was calculated as relative fitness compared to the T/F virus over the course of the infection. Specifically, fitness of the viral population was estimated for the six chronic progressors (<xref ref-type="table" rid="table2">Table 2</xref>) in regions NS2, NS3, and NS5B and for each epitope, the population average relative fitness of the viral population over the course of infection was measured (<xref ref-type="table" rid="table3 table4">Tables 3 and 4</xref>, <xref ref-type="supplementary-material" rid="supp3 supp4 supp5 supp6">Supplementary files 3–6</xref>).</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Co-occurring mutations, epitope escape mutants, and the associated frequency of occurrence and relative fitness of the NS3 region of subject THDS1086MX.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Time</th><th align="left" valign="bottom">Viral load (IU/ml)</th><th align="left" valign="bottom">Frequency</th><th align="left" valign="bottom">Relative fitness</th><th align="left" valign="bottom"><sub>1406</sub>KLVAMGLNAV<sub>1415</sub>mutations</th><th align="left" valign="bottom" colspan="3">Co-occurring mutations<xref ref-type="table-fn" rid="table3fn2"><sup>†</sup></xref></th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="8">16DPI</td><td align="left" valign="bottom" rowspan="8">235662</td><td align="left" valign="bottom">61.70%</td><td align="left" valign="bottom">1.000</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">18.10%</td><td align="left" valign="bottom">1.000</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">6.00%</td><td align="left" valign="bottom">1.000</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">4.80%</td><td align="left" valign="bottom">0.364</td><td align="left" valign="bottom">V1408A</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">4.60%</td><td align="left" valign="bottom">1.000</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">1.70%</td><td align="left" valign="bottom">1.000</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">1.60%</td><td align="left" valign="bottom">0.364</td><td align="left" valign="bottom">V1408A</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">1.40%</td><td align="left" valign="bottom">1.000</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom" rowspan="9">72DPI</td><td align="left" valign="bottom" rowspan="9">176550</td><td align="left" valign="bottom">48.50%</td><td align="left" valign="bottom">0.453</td><td align="left" valign="bottom"/><td align="left" valign="bottom">H1115T</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">24.70%</td><td align="left" valign="bottom">0.453</td><td align="left" valign="bottom"/><td align="left" valign="bottom">H1115T</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">6.20%</td><td align="left" valign="bottom">0.453</td><td align="left" valign="bottom"/><td align="left" valign="bottom">H1115T</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">6.20%</td><td align="left" valign="bottom">0.453</td><td align="left" valign="bottom"/><td align="left" valign="bottom">H1115T</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">3.70%</td><td align="left" valign="bottom">0.084</td><td align="left" valign="bottom"/><td align="left" valign="bottom">H1115T</td><td align="left" valign="bottom">C1318Y</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">3.60%</td><td align="left" valign="bottom">0.453</td><td align="left" valign="bottom"/><td align="left" valign="bottom">H1115T</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">3.30%</td><td align="left" valign="bottom">0.453</td><td align="left" valign="bottom"/><td align="left" valign="bottom">H1115T</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">2.10%</td><td align="left" valign="bottom">0.084</td><td align="left" valign="bottom"/><td align="left" valign="bottom">H1115T</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">1.80%</td><td align="left" valign="bottom">0.069</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">H1115T</td><td align="left" valign="bottom">C1318Y</td><td align="left" valign="bottom">V1458A</td></tr><tr><td align="left" valign="bottom" rowspan="13">109DPI</td><td align="left" valign="bottom" rowspan="13">108737</td><td align="left" valign="bottom">35.80%</td><td align="left" valign="bottom">0.223</td><td align="left" valign="bottom">I1412V</td><td align="left" valign="bottom">H1115S</td><td align="left" valign="bottom">R1118H</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">19.10%</td><td align="left" valign="bottom">0.384</td><td align="left" valign="bottom">I1412L</td><td align="left" valign="bottom">H1115S</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">8.60%</td><td align="left" valign="bottom">0.910</td><td align="left" valign="bottom">I1412L</td><td align="left" valign="bottom">V1112A</td><td align="left" valign="bottom">H1115S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">7.70%</td><td align="left" valign="bottom">0.360</td><td align="left" valign="bottom">I1412L</td><td align="left" valign="bottom">V1112I</td><td align="left" valign="bottom">H1115S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">6.30%</td><td align="left" valign="bottom">0.061</td><td align="left" valign="bottom">I1412L</td><td align="left" valign="bottom">H1115G</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">5.70%</td><td align="left" valign="bottom">0.247</td><td align="left" valign="bottom">I1412L</td><td align="left" valign="bottom">H1115T</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">3.70%</td><td align="left" valign="bottom">0.657</td><td align="left" valign="bottom">I1412L</td><td align="left" valign="bottom">V1112T</td><td align="left" valign="bottom">H1115S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">2.60%</td><td align="left" valign="bottom">0.145</td><td align="left" valign="bottom">I1412L</td><td align="left" valign="bottom">V1112A</td><td align="left" valign="bottom">H1115T</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">2.30%</td><td align="left" valign="bottom">0.062</td><td align="left" valign="bottom">I1412L</td><td align="left" valign="bottom">V1112I</td><td align="left" valign="bottom">H1115G</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">2.20%</td><td align="left" valign="bottom">0.229</td><td align="left" valign="bottom">I1412L</td><td align="left" valign="bottom">V1112I</td><td align="left" valign="bottom">H1115T</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">2.20%</td><td align="left" valign="bottom">0.573</td><td align="left" valign="bottom">I1412L</td><td align="left" valign="bottom">V1112A</td><td align="left" valign="bottom">H1115T</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">2.10%</td><td align="left" valign="bottom">0.624</td><td align="left" valign="bottom">I1412V</td><td align="left" valign="bottom">H1115S</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">1.80%</td><td align="left" valign="bottom">0.309</td><td align="left" valign="bottom">I1412L</td><td align="left" valign="bottom">H1115A</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom" rowspan="8">198DPI</td><td align="left" valign="bottom" rowspan="8">681389</td><td align="left" valign="bottom">73.60%</td><td align="left" valign="bottom">0.360</td><td align="left" valign="bottom">I1412L</td><td align="left" valign="bottom">V1112I</td><td align="left" valign="bottom">H1115S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>12.60%</bold></td><td align="left" valign="bottom"><bold>2.149</bold></td><td align="left" valign="bottom"><bold>I1412L</bold><xref ref-type="table-fn" rid="table3fn1">*</xref></td><td align="left" valign="bottom"><bold>V1112I</bold></td><td align="left" valign="bottom"><bold>H1115S</bold></td><td align="left" valign="bottom"><bold>A1593V</bold></td></tr><tr><td align="left" valign="bottom"><bold>4.70%</bold></td><td align="left" valign="bottom"><bold>1.683</bold></td><td align="left" valign="bottom"><bold>A1409T</bold></td><td align="left" valign="bottom"><bold>V1112P</bold></td><td align="left" valign="bottom"><bold>H1115S</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">2.90%</td><td align="left" valign="bottom">0.360</td><td align="left" valign="bottom">I1412L</td><td align="left" valign="bottom">V1112I</td><td align="left" valign="bottom">H1115S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">1.80%</td><td align="left" valign="bottom">0.360</td><td align="left" valign="bottom">I1412L</td><td align="left" valign="bottom">V1112I</td><td align="left" valign="bottom">H1115S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>1.70%</bold></td><td align="left" valign="bottom"><bold>1.683</bold></td><td align="left" valign="bottom"><bold>A1409T</bold></td><td align="left" valign="bottom"><bold>V1112P</bold></td><td align="left" valign="bottom"><bold>H1115S</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">1.60%</td><td align="left" valign="bottom">0.066</td><td align="left" valign="bottom">I1412L</td><td align="left" valign="bottom">V1112I</td><td align="left" valign="bottom">H1115S</td><td align="left" valign="bottom">M1268I</td></tr><tr><td align="left" valign="bottom">1.20%</td><td align="left" valign="bottom">0.360</td><td align="left" valign="bottom">I1412L</td><td align="left" valign="bottom">V1112I</td><td align="left" valign="bottom">H1115S</td><td align="left" valign="bottom"> </td></tr></tbody></table><table-wrap-foot><fn id="table3fn1"><label>*</label><p>Bold - indicate escape variants with fitness estimate ≥1.</p></fn><fn id="table3fn2"><label>†</label><p>Only non-synonymous mutations are shown.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Co-occurring mutations, epitope escape mutants, and the associated frequency of occurrence and relative fitness of NS3 region of subject THGS0684MX.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Time</th><th align="left" valign="bottom">Viral load (IU/ml)</th><th align="left" valign="bottom">Frequency</th><th align="left" valign="bottom">Relative fitness</th><th align="left" valign="bottom"><sub>1325</sub>SILGIGTAL<sub>1333</sub>Mutations</th><th align="left" valign="bottom" colspan="2">Co-occurring mutations<xref ref-type="table-fn" rid="table4fn1">*</xref></th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="5">2DPI</td><td align="left" valign="bottom" rowspan="5">140,200</td><td align="left" valign="bottom">87.9%</td><td align="left" valign="bottom">1.000</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">4.8%</td><td align="left" valign="bottom">0.148</td><td align="left" valign="bottom"/><td align="left" valign="bottom">G1076W</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">3.2%</td><td align="left" valign="bottom">1.000</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">3%</td><td align="left" valign="bottom">0.155</td><td align="left" valign="bottom"/><td align="left" valign="bottom">G1076R</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">1.1%</td><td align="left" valign="bottom">0.022</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">G1076W</td><td align="left" valign="bottom">Y1521C</td></tr><tr><td align="left" valign="bottom" rowspan="5">58DPI</td><td align="left" valign="bottom" rowspan="5">19,932</td><td align="left" valign="bottom">74.2%</td><td align="left" valign="bottom">1.000</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">10.8%</td><td align="left" valign="bottom">1.000</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">8.4%</td><td align="left" valign="bottom">0.322</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">5.5%</td><td align="left" valign="bottom">0.162</td><td align="left" valign="bottom"/><td align="left" valign="bottom">M1649T</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">1%</td><td align="left" valign="bottom">0.322</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">S1289G</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom" rowspan="2">184DPI</td><td align="left" valign="bottom" rowspan="2">221,964</td><td align="left" valign="bottom"><bold>90.9%</bold></td><td align="left" valign="bottom"><bold>1.042</bold></td><td align="left" valign="bottom"><bold>A1332V</bold><xref ref-type="table-fn" rid="table4fn2"><sup>†</sup></xref></td><td align="left" valign="bottom"><bold>P1496S</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">9.1%</td><td align="left" valign="bottom">0.157</td><td align="left" valign="bottom">A1332V</td><td align="left" valign="bottom">D1316G</td><td align="left" valign="bottom">P1496S</td></tr></tbody></table><table-wrap-foot><fn id="table4fn1"><label>*</label><p>Only non-synonymous mutations are shown.</p></fn><fn id="table4fn2"><label>†</label><p>Bold - indicate escape variants with fitness estimate ≥1.</p></fn></table-wrap-foot></table-wrap><p>In general, in the six subjects who progressed to chronic infection, there was a decrease in average relative fitness in the period of &lt;90 DPI with respect to the T/F virus (<xref ref-type="fig" rid="fig2">Figure 2</xref>). This was with the exception of subject 300023 which can be explained by the presence of two T/F viruses (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) where the observed mutations responsible for the increase in viral fitness were present in the genome of the second T/F virus detected at 44DPI carrying substitutions H2750Q and T2917A (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2A</xref>; <xref ref-type="bibr" rid="bib5">Bull et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Longitudinal fitness plots of subjects chronically infected with HCV.</title><p>Longitudinal fitness plots of subjects (<bold>A</bold>) 300023, (<bold>B</bold>) 300240, (<bold>C</bold>) 300256, (<bold>D</bold>) HOKD0485FX, (<bold>E</bold>) THDS1086MX and (<bold>F</bold>) THGS0684MX are shown. Gray shade indicates viral load and is measured in IU/ml on the right y-axis. Colored lines indicate population average relative fitness estimate (right y-axis) for protein regions (see key). Vertical bars indicate standard deviation of population average relative fitness.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data containing Days post infection, viral load and NS2, NS3, NS5B fitness estimate data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102232-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102232-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Phylogenetic analysis of subject 300023 NS5B region.</title><p>Diamonds represent haplotypes with blue indicating consensus sequence and green diamonds representing reconstructed haplotypes at 36DPI. Purple diamonds indicate reconstructed haplotypes at 44DPI. The NS5B region shows diversity consistent with the presence of two T/F viruses as previously described by us (<xref ref-type="bibr" rid="bib5">Bull et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>; <xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102232-fig2-figsupp1-v1.tif"/></fig></fig-group><p>To understand the observed reduction in viral fitness within the first 90 DPI, a statistical analysis was performed to examine the relationship between population fitness and immune escape (ϵ), IFN-γ ELISPOT responses, and SE values (<xref ref-type="fig" rid="fig3">Figure 3</xref>). In the &lt;90 DPI period, a significant positive correlation (Pearson’s correlation = 0.84, p-value = 0.0004) was identified between population average relative fitness and IFN-γ ELISPOT response (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). A significant negative correlation between fitness estimate and SE (Pearson’s correlation = –0.48, p-value = 0.01) was also identified in the &lt;90 DPI period (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). No significant correlation was observed between ϵ and fitness estimates at &lt;90 DPI (Pearson’s correlation = 0.34, p-value = 0.32; <xref ref-type="fig" rid="fig3">Figure 3C</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>The relationship between fitness and the magnitude of the immune response (SE and IFN-γ ELISPOT) and the rate of escape at &lt;90 DPI and &gt;90 DPI.</title><p>The relationship of population fitness against (<bold>A</bold>) average IFN-γ ELISPOT, (<bold>B</bold>) average Shannon entropy (SE), and (<bold>C</bold>) rate of escape at &lt;90 DPI (green) was measured by Pearson’s correlation. The relationship of population fitness against (<bold>D</bold>) average IFN-γ ELISPOT, (<bold>E</bold>) average Shannon entropy (SE), and (<bold>F</bold>) rate of escape at &gt;90 DPI (purple) was also measured by Pearson’s correlation. p-Values (P) and Pearson’s correlation coefficient (R) are shown in the top left corner of each panel.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source data containing SE, IFN-y ELISPOT and the rate of escape data at &gt;90DPI and &lt;90DPI.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102232-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102232-fig3-v1.tif"/></fig><p>Similar to the analysis performed at &lt;90 DPI, correlation tests were performed to understand the change in fitness at &gt;90 DPI (<xref ref-type="fig" rid="fig3">Figure 3</xref>). No significant correlations were observed between the average relative fitness estimates and IFN-γ ELISPOT (Pearson’s correlation = 0.55, p-value = 0.25, <xref ref-type="fig" rid="fig3">Figure 3D</xref>), SE (Pearson’s correlation = 0.26, p-value = 0.26, <xref ref-type="fig" rid="fig3">Figure 3E</xref>), and ϵ (Pearson’s correlation = 0.39, p-value = 0.31, <xref ref-type="fig" rid="fig3">Figure 3F</xref>).</p><p>Overall, these results suggest that in the early phase when the T/F virus was the major variant, a fit viral population was targeted by a strong CD8 +T cell response. Mutations away from the T/F virus then reduced fitness. Insignificant correlations observed in &gt;90 DPI also confirmed that once the chronic phase population had adapted against host immune response, immune pressure showed less impact on viral population fitness and diversity when compared to &lt;90 DPI.</p></sec><sec id="s2-4"><title>Viral fitness rebounds with co-occurring mutations after the second genetic bottleneck at &gt;90 DPI</title><p>After the second genetic bottleneck at &gt;90 DPI, when viral load begins to rise, the distribution of relative fitness continued to decrease in most genomic regions analyzed for all six chronic progressors (<xref ref-type="fig" rid="fig2">Figure 2</xref>). However, THDS1086MX and THGS0684MX showed a contrasting pattern where the relative fitness measured for the NS3 region exceeded the fitness measured for the T/F virus, while the relative fitness decreased for the viral variants in comparison to the fitness of the T/F virus in the NS5B region (<xref ref-type="fig" rid="fig2">Figure 2E–F</xref>). Of note, THDS1086MX and THGS0684MX are purported to be recipients from the same donor and share an identical consensus sequence at &lt;16 DPI (; <xref ref-type="bibr" rid="bib46">Walker et al., 2016</xref>). Furthermore, the pair carries the same HLA-A alleles but different HLA-B alleles (<xref ref-type="table" rid="table1">Table 1</xref>). We wanted to explore the NS3 regions of THDS1086MX and THGS0684MX to further understand the specific mutations contributing to their relative fitness rebound and to elucidate the mechanisms driving viral evolution and adaptation in these individuals.</p><p>Further analysis revealed a complex pattern of evolution characterized by multiple sets of co-occurring mutations (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="table" rid="table3">Table 3</xref>). In subject THDS1086MX, at 16DPI, viral haplotypes did not carry any co-occurring mutations. However, at 72DPI, a set of three mutations (H1115T, V1458A, C1318Y) was found to be co-occurring within the same viral variant, with its relative fitness estimated to be inferior to the T/F virus (relative fitness = 0.069; <xref ref-type="table" rid="table3">Table 3</xref>). At 109DPI, multiple combinations of co-occurring mutations were observed. In particular, immune escape mutation 1406KLVAMG(I\L)NAV1415 was identified co-occurring with H1115S/G/T and V1112A/I/T. Variants carrying I1412L and H1115S had a relative fitness of at least one third of the T/F virus. The combination of 1406KLVAMG(I\L)NAV1415, H1115S, and V1112A reached a fitness level nearly equal to the T/F variant (relative fitness of 0.91, <xref ref-type="table" rid="table3">Table 3</xref>). This suggested a 90% restoration of fitness compared to the T/F virus when H1115S and V1112A were combined with the immune escape mutation. Notably, a variant with only 1406KLVAMG(I\L)NAV1415 and H1115S exhibited positive epistasis, with a relative fitness of 0.384.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Longitudinal co-occurring mutations in the NS3 region for subjects THDS1086MX and THGS0684MX.</title><p>Highlighter plots (Geneious Prime 2023) derived from longitudinal sequencing from subjects THDS1086MX (top) and THGS0684MX (bottom) indicating co-occurring mutations relative to the transmitted/founder (TF) across the NS3 region. Numbers above highlighter plots denote the genomic amino acid number for the NS3 region. Sequences are labeled by frequency of occurrence (%) and days post infection (DPI). Specific amino acid changes are shown in <xref ref-type="table" rid="table3 table4">Tables 3 and 4</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102232-fig4-v1.tif"/></fig><p>Viral variants with higher fitness than the T/F virus of subject THDS1086MX were observed at 198DPI (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="table" rid="table3">Table 3</xref>). One variant carried the epitope mutation 1406KLVAMG(I\L)NAV1415 with V1112I, H1115S, and an additional mutation A1593V, achieving a relative fitness of 2.14 at a frequency of 12.6%. Another variant with only 1406KLVAMG(I\L)NAV1415 V1112I and H1115S, occurring at 73.6%, showed a relative fitness of 0.360. Additionally, a new immune escape mutation, A1409L, co-occurred with V1112P and H1115S at a frequency of 4.70% and exhibited a relative fitness greater than the T/F (relative fitness = 1.68). The combination of <sub>1406</sub>KLV(A\T)MGINAV<sub>1415</sub>, V1112P, and H1115S did not co-occur with <sub>1406</sub>KLVAMG(I\L)NAV<sub>1415</sub>, V1112I, and H1115S, indicating a diversifying strategy for host adaptation. Overall, the combination of I1412L, V1112I, and H1115S emerged as the most advantageous mutation combination, enhancing virus fitness and reaching fixation in the viral population over the course of infection.</p><p>For THGS0684MX, co-occurring mutations in the NS3 region occurred in a much simpler fashion (<xref ref-type="table" rid="table4">Table 4</xref>), where the immune escape mutation 1325SILGIGT(A\V)L1333 achieved a relative fitness of 1.042 when co-occurring with P1496S. The effect of the synergistic mutations was also reflected in the fact that this variant reached 90.9% frequency of occurrence in the viral population at the last sequenced time point of 184DPI (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="table" rid="table4">Table 4</xref>).</p><p>To determine if the increase in estimated fitness was associated with reversion events, namely mutations towards common circulating variants that are assumed to be a more fit HCV strain (generated as previously described <xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>). A comparison of the non-synonymous mutations at the final sequence time point in both subjects THDS1086MX and THGS0684MX to the global Genbank genotype 1 a consensus sequence was performed. This revealed that V1112P and A1593V (12.6% frequency) in subject THDS1086MX were both reversions toward the worldwide consensus (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="table" rid="table3">Table 3</xref>). Similarly, for subject THGS0684MX, the mutation A1332Y (90.9% frequency) also reverted to the global consensus strain (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="table" rid="table4">Table 4</xref>).</p><p>These findings suggest rapid adaptation of chronic HCV variants post-strong CD8 +T cell responses during acute infection, supported by positive epistasis via compensatory mutations post-second genetic bottleneck. Variations between subjects with identical T/F viruses imply a unique fitness restoration strategy for each individual rather than a universal mutation pattern across subjects sharing the same T/F variant.</p></sec><sec id="s2-5"><title>In chronic progressors, nAbs emerge after CD8+ T-cells and coincide with the rebound of viral fitness</title><p>Previously, we have shown that an early nAb response is associated with clearance (<xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>). In those that develop chronic infection, nAb activity is truly delayed and develops towards longitudinal variants after the T/F is cleared (<xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>). Furthermore, we have shown previously (<xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>) that CD8 +T cell responses impose a strong selective force on the T/F virus population, thus contributing to its extinction and to the rise of the escape variants with the establishment of chronic infection. Here, a comprehensive analysis integrating nAb responses, CD8 +T cell responses, and viral fitness was performed to elucidate the dynamic interplay between the adaptive immune system and viral evolution and fitness.</p><p>All six chronic subjects included in this study had data for nAb responses (<xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>), IFN-γ ELISPOT responses, and viral fitness readily available. A subset of three clearer subjects had data for nAb responses (<xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>) and IFN-γ ELISPOT responses (<xref ref-type="fig" rid="fig5">Figure 5</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). As mentioned above, viral fitness could not be estimated for clearer subjects due to a lack of non-synonymous fixation mutations occurring within epitope regions.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>HCV neutralizing antibody (nAb), CD8 +T cell responses, and viral fitness.</title><p>The timing (Days post-infection) of CD8 +T cell and nAbs is compared for clearer subjects (<bold>A</bold>) and chronic subjects (<bold>B</bold>). Statistical significance (Wilcoxon matched-pairs signed rank test) is represented by asterisks (p&lt;0.05 (*)) and non-significance by NS. (<bold>C-E</bold>) show three representative subjects who developed chronic HCV infection. The blue line represents the IFN-γ ELISPOT (SFU/million). The maroon line represents HCV nAb ID50 titer with squares representing timepoints tested on autologous virus and circles representing timepoints tested on heterologous virus. Population average relative fitness estimate of regions NS5B (purple), NS3 (green), and NS2 (pink) is shown. Black arrows represent increases in average relative fitness. Neutralization results were generated from multiple biological samples with each sample assayed in technical quadruplicates across two independent experiments.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Source data containing viral load, CD8 T cell, neutralisation and fitness data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102232-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102232-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>HCV neutralizing antibody (nAb) and CD8 +T cell responses and viral fitness.</title><p>(<bold>A-C</bold>) show 3 subjects who cleared HCV infection and (<bold>D-F</bold>) show three subjects who developed chronic HCV infection. The blue line represents the IFN-γ ELISPOT response (SFU/million). The maroon line represents HCV nAb ID50 titer with squares representing timepoints tested on autologous virus and circles representing timepoints tested on heterologous virus. The green line illustrates average relative fitness values. (<bold>A-C</bold>) The shaded area represents the longitudinal HCV RNA levels (IU/ml). (<bold>D-F</bold>) Population average relative fitness estimates of regions are shown (see key).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102232-fig5-figsupp1-v1.tif"/></fig></fig-group><p>The timing of the first nAb responses and the IFN-γ ELISPOT response were assessed to elucidate the dynamics of both CD8 +T cell and nAb responses and their role in clearance or chronic outcomes. In the subset of three clearer subjects (those tested for both nAb responses <xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref> and IFN-γ ELISPOT responses) no significant difference was found in the timing of nAb and IFN-γ ELISPOT responses, with both responses emerging in all three subjects at &lt;100 DPI (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). However, for chronic progressors, IFN-γ ELISPOT responses were first detectable at an average of 48 DPI (range 30–80 DPI) whereas nAb responses occurred significantly later, with an average onset of 465 DPI (range 74–945 DPI), indicating a notable delay compared to CD8 +T cell responses (p=0.0313, Wilcoxon matched-pairs signed rank test, <xref ref-type="fig" rid="fig5">Figure 5B</xref>).</p><p>Interestingly, in subjects THDS1086MX and THGS0684MX, we observed escape variants with higher relative fitness emerging concurrently with the onset of nAbs at 198 and 184 DPI, respectively (<xref ref-type="fig" rid="fig5">Figure 5E and F</xref>). Additionally, upon the appearance of nAbs, there was a decline in IFN-γ ELISPOT towards the selected epitopes, while nAb responses remained stable. This suggests a transition from CD8 +T cell-dominant immune responses to nAb-dominant immune responses. It’s noteworthy that a similar pattern was observed in subject 300023, where an increase in viral fitness coincided with a weak but detectable nAb response towards the T/F virus at 74 DPI (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Nevertheless, nAbs were undetectable at the subsequent timepoint while the IFN-γ ELISPOT response dominated until 200 DPI when nAb responses reappeared and increased along with IFN-γ ELISPOT. This suggests that nAbs were ineffective in controlling the virus in subject 300023 during this period (&lt;100 DPI). For the other three subjects, no consistent pattern was observed (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Specifically, for subjects HOKD0485FX and 300256, nAbs emerged well after viral decline, and there was a lack of CD8 +T cell data at the positive nAb timepoints, while for subject 300240 both IFN-γ ELISPOT and nAb responses increased after 300DPI.</p><p>Together, these results show that an early and strong CD8 +T cell response in the absence of nAbs imposes a strong selective force on the T/F virus population, enabling the virus to escape and establish chronic infection.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Using a rare cohort of very recently infected individuals, we report the dynamics of evolution of the viral quasispecies and the role of the host cytotoxic T-cell and nAb responses during the acute phase of primary HCV infection. We show that viral fitness decreases during the first 90DPI associated with the magnitude of CD8 +T cell responses and the initial level of diversification. Thereafter, viral fitness rebounds in a complex pattern of evolution characterized by multiple sets of co-occurring mutations. Finally, within this cohort of very recently HCV-infected individuals, we show that an early and strong CD8 +T cell response in the absence of nAbs imposes a strong selective force on the T/F virus population, enabling the virus to escape and establish chronic infection. Understanding these dynamics is crucial for developing effective vaccines for HCV.</p><p>We have previously demonstrated in HCV that a genetic bottleneck occurs in the viral population at around three months post-infection, where the T/F is replaced with new viral variants that dominate infection (<xref ref-type="bibr" rid="bib5">Bull et al., 2011</xref>; <xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>) and this genetic bottleneck event was similarly reported in the case of early HIV infection (<xref ref-type="bibr" rid="bib27">Li et al., 2016</xref>). In fact, many parallels can be drawn between HIV infections and HCV infections in the context of emerging viral species that escape T cell immune responses. For example, these new variants carry amino acid changes across the viral genome, including HLA-I restricted epitopes, highlighting that T-cell responses, in the absence of nAbs, play a significant role in driving immune escape. (<xref ref-type="bibr" rid="bib5">Bull et al., 2011</xref>; <xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>; <xref ref-type="bibr" rid="bib22">Kuntzen et al., 2007</xref>; <xref ref-type="bibr" rid="bib20">Kantzanou et al., 2003</xref>). Nevertheless, the majority of studies on HCV CD8 +T cell responses to date focus only on the epitope and its escape variant without analyzing viral fitness or surrounding mutations which co-occur with the immune escape mutation (<xref ref-type="bibr" rid="bib10">Campo et al., 2014</xref>). One major difference between HCV and HIV infection is the event where patients infected with HCV have an approximately 25% chance to naturally clear the infection as opposed to just achieving viral control in HIV infections. Here, we probed the underlying mechanism and questioned how the host immune response and HCV mutational landscape can allow the virus to escape the immune system. To understand this process, taking inspiration from HIV studies (<xref ref-type="bibr" rid="bib3">Barton et al., 2016</xref>), a quantitative analysis of viral fitness relative to viral haplotypes was conducted using longitudinal samples to investigate whether a similar phenomenon was identified in HCV infections for our cohort of patients who progress to chronic infection. We observed a decrease in population average relative fitness in the period of &lt;90 DPI with respect to the T/F virus in chronic subjects infected with HCV. The decrease in fitness correlated positively with IFN-γ ELISPOT responses and negatively with SE, indicating that CD8 +T cell responses drove the rapid emergence of immune escape variants, which initially reduced viral fitness. This is similarly reflected in HIV-infected patients where strong CD8 +T cell responses drove quicker emergence of immune escape variants, often accompanied by compensatory mutations (<xref ref-type="bibr" rid="bib3">Barton et al., 2016</xref>).</p><p>While a recent HCV infection study examined mutations in the E2 region, revealing that certain co-occurring mutations led to a loss of E2 function in clearers but a gain in function for chronic progressors (<xref ref-type="bibr" rid="bib14">Frumento et al., 2024</xref>), the impact of co-occurring mutations in the nonstructural regions on HCV outcomes remains largely unexplored (<xref ref-type="bibr" rid="bib9">Campo et al., 2008</xref>; <xref ref-type="bibr" rid="bib10">Campo et al., 2014</xref>; <xref ref-type="bibr" rid="bib2">Aurora et al., 2009</xref>; <xref ref-type="bibr" rid="bib30">Murray et al., 2013</xref>). Furthermore, previous studies on HCV have not integrated CD8 +T cell responses, longitudinal tracking of immune escape mutations, co-occurring mutations, and fitness estimation to analyze HCV evolutionary mechanisms (<xref ref-type="bibr" rid="bib26">Leung et al., 2014</xref>). Combining these approaches provides a clearer understanding of HCV evolution by showing how co-occurring mutations impact viral survival over time. We observed that in some subjects, combinations of mutations could compensate for the negative fitness cost of immune escape, leading to a rebound in viral fitness during infection. This was not observed in all subjects and indicates that each subject’s mutation strategy is unique, even when there are shared HLA alleles (such as for subjects THDS1086MX and THGS0684MX). Additionally, as described in Barton et al.’s study, it is quite possible that due to the sequence background (i.e. the T/F virus sequence composition), combined with unique immune pressure exerted by individual hosts, there exist multiple paths for immune escapes with diversifying levels of fitness (<xref ref-type="bibr" rid="bib3">Barton et al., 2016</xref>).</p><p>When the analysis of nAb responses, CD8 +T cell responses, and viral fitness was performed, it was interesting to note the opposite trend with regards to the humoral response in these same subjects. While it remains unclear how T- and B-cell components of the immune system might co-operate to confer protection, the findings of the current study strongly suggest that the absence of nAbs in chronic progressors enables viruses to continue to infect new cells, replicate, and mutate. This suggests a synergistic interaction between B and T-cell responses targeting the virus, emphasizing the importance of their co-occurrence. Although several studies have alluded to this (<xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>; <xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>), none have directly compared longitudinal B and T-cell responses in recent clearers versus chronic progressors. In chronic subjects, increased viral fitness after the genetic bottleneck aligned with nAb onset (<xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>; <xref ref-type="bibr" rid="bib14">Frumento et al., 2024</xref>). Our fitness model, using the T/F virus as a baseline, enables tracking of relative viral fitness changes over time. Here, nAb appearance coincided with declining IFN-γ ELISPOT responses (<xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>) towards selected epitopes that showed evidence of escape, suggesting a shift from CD8 +T cell to nAb responses.</p><p>While our findings here are promising, it should be recognized that although the bioinformatics tool (iedb_tool.py) proved useful for identifying potential epitopes, there could be epitopes that are not predicted or false positives from the output, which could lead to missing real epitopes.</p><p>In conclusion, this study provides initial insights into the evolutionary dynamics of HCV, showing that an early, robust CD8 +T cell response without nAbs strongly selects against the T/F virus, enabling it to escape and establish chronic infection. However, these findings are preliminary and not exhaustive, warranting further investigation to fully understand these dynamics. Nevertheless, the work presented here could explain the lack of association with a lower incidence of chronic HCV infection compared to placebo observed in the recent Phase I/II trials of the ChAd3-NSmut and MVA-NSmut vaccines, which aimed to induce T cell responses by encoding HCV NS proteins (<xref ref-type="bibr" rid="bib33">Page et al., 2021</xref>). While much work is still required to be able to fully understand the factors contributing to the overall dynamics of HCV infections, this work has the potential to inform the design of the next generation of vaccines.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Lenti-X 293T Cell Line</td><td align="left" valign="bottom">Takara, Mountain View, CA, USA</td><td align="left" valign="bottom">Cat# 632180</td><td align="left" valign="bottom">Cell line maintained in High Glucose Dulbecco’s Modified Eagle Medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Huh7.5</td><td align="left" valign="bottom">Apath, New York, NY, USA</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell line maintained in High Glucose Dulbecco’s Modified Eagle Medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Photinus pyralis</italic>)</td><td align="left" valign="bottom">pTG126 MLV luciferase</td><td align="left" valign="bottom">Prof. Francois-Loic Cosset; <xref ref-type="bibr" rid="bib4">Bartosch et al., 2003</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Vector to produce HCVpp</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>murine leukemia virus</italic>)</td><td align="left" valign="bottom">phCMV-5349 MLV gag/pol</td><td align="left" valign="bottom">Prof. Francois-Loic Cosset</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">CD8 T-cell<break/>(9-10mers)</td><td align="left" valign="bottom">Mimotopes</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mammalian Calphos transfection kit</td><td align="left" valign="bottom">Macherey-Nagel</td><td align="left" valign="bottom">Cat#631312</td><td align="left" valign="bottom">For HCVpp transfection</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ShoRAH</td><td align="left" valign="bottom">ShoRAH</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_005211">SCR_005211</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">LoFreq</td><td align="left" valign="bottom">LoFreq</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_013054">SCR_013054</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Geneious</td><td align="left" valign="bottom">Geneious</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_010519">SCR_010519</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">QuasiRecomb</td><td align="left" valign="bottom">QuasiRecomb</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_008812">SCR_008812</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_000306">SCR_000306</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Immune Epitope Database and Analysis Resource (IEDB)</td><td align="left" valign="bottom">Immune Epitope Database and Analysis Resource (IEDB)</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_006604">SCR_006604</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Python</td><td align="left" valign="bottom">Python</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_008394">SCR_008394</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">RStudio</td><td align="left" valign="bottom">RStudio</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_000432">SCR_000432</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ShoRAH</td><td align="left" valign="bottom">ShoRAH</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_005211">SCR_005211</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">LoFreq</td><td align="left" valign="bottom">LoFreq</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_013054">SCR_013054</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Geneious</td><td align="left" valign="bottom">Geneious</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_010519">SCR_010519</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">QuasiRecomb</td><td align="left" valign="bottom">QuasiRecomb</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_008812">SCR_008812</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Subjects and samples</title><p>Samples were available from two prospective cohorts of HCV-seronegative and aviremic, high-risk, individuals enrolled in the Hepatitis C Incidence and Transmission Studies (HITS) in prisons (HITS-p), or in the general community (HITS-c), as previously described (<xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Walker et al., 2016</xref>; <xref ref-type="bibr" rid="bib11">Cunningham et al., 2017</xref>; <xref ref-type="bibr" rid="bib49">White et al., 2014</xref>). Risk behavior data and blood samples were collected every six months to screen for HCV RNA positivity and seroconversion. Participants identified as early incident cases were enrolled into a sub-cohort called HITS-incident (HITS-i) upon detection of new onset viremia without antibodies, as described previously (<xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>). These subjects were then frequently sampled for 12 weeks before being offered antiviral treatment at 24 weeks, allowing for the classification of outcomes as either natural clearance or chronic infection. The date of infection was estimated by subtracting the average HCV pre-seroconversion window period, which has been estimated at 51 days from the midpoint between last seronegative and first seropositive time points as previously described (<xref ref-type="bibr" rid="bib5">Bull et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>; <xref ref-type="bibr" rid="bib34">Page-Shafer et al., 2008</xref>; <xref ref-type="bibr" rid="bib17">Glynn et al., 2005</xref>). Molecular HLA typing was performed at the Institute of Immunology and Infectious Diseases in Perth, Australia, using second-generation sequencing of HLA-A/B/C genes as previously described (<xref ref-type="bibr" rid="bib16">Gaudieri et al., 2006</xref>). 14 subjects with stored peripheral blood mononuclear cells (PBMCs) were selected from the HITS-i cohort. This group included eight subjects with acute HCV infection and six subjects who developed chronic infection.</p><p>PBMCs were isolated from peripheral blood via density-based centrifugation and resuspended in RPMI (Sigma-Aldrich, MO) supplemented with penicillin, streptomycin, l-glutamine, and fetal bovine serum at 1×10<sup>6</sup> cells/mL.</p></sec><sec id="s4-2"><title>Viral sequencing and identification of T/Fs and longitudinal variants</title><p>Near full-length HCV genome amplification and sequencing datasets of the full-length viral genomes at multiple time points have been published previously (<xref ref-type="bibr" rid="bib5">Bull et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>; <xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>; <xref ref-type="bibr" rid="bib7">Bull et al., 2016</xref>; <xref ref-type="bibr" rid="bib38">Rodrigo et al., 2017</xref>). Briefly, near full-length HCV genome amplification was performed using an nRT-PCR (<xref ref-type="bibr" rid="bib7">Bull et al., 2016</xref>). Illumina (MiSeq Benchtop sequence, San Diego, USA) sequencing was performed on amplicons from longitudinal time points of the 14 subjects (<xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>; <xref ref-type="bibr" rid="bib7">Bull et al., 2016</xref>). A bioinformatics pipeline was used to clean and align reads generated from next-generation sequencing (NGS; <xref ref-type="bibr" rid="bib5">Bull et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>; <xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>). To accurately detect single nucleotide polymorphisms (SNPs) from the aligned and cleaned sequences, analysis was performed to correct for random technical errors using the software ShoRAH, LoFreq, and Geneious (<xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>; <xref ref-type="bibr" rid="bib52">Zagordi et al., 2011</xref>; <xref ref-type="bibr" rid="bib51">Wilm et al., 2012</xref>). Haplotypes were reconstructed from NGS data across the full genome using ShoRAH and QuasiRecomb (<xref ref-type="bibr" rid="bib52">Zagordi et al., 2011</xref>; <xref ref-type="bibr" rid="bib44">Töpfer et al., 2013</xref>). As described previously (<xref ref-type="bibr" rid="bib5">Bull et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>; <xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>), to determine T/Fs, a statistical model, Poisson fitter, as well as phylogenetic analysis was applied to haplotypes from the first available viremic timepoint but prior to the first HCV antibodies (seroconversion) detection, for each subject to determine the T/F (<xref ref-type="bibr" rid="bib39">Salazar-Gonzalez et al., 2009</xref>). Shannon Entropy (SE) was determined from the NGS data as previously described (<xref ref-type="bibr" rid="bib5">Bull et al., 2011</xref>) with modifications to extend to individual protein regions (namely NS2, NS3, and NS5B). Briefly, SE was calculated using the frequency of occurrence of SNPs based on per codon position, this was further normalized by the length of the number of codons in the sequence which made up respective protein. An average SE value was calculated for each time point in each protein region for all subjects until the fixation event.</p></sec><sec id="s4-3"><title>CD8+ T-cell epitope selection</title><p>For each of the 14 subjects, non-synonymous fixation events (&gt;70% frequency in the viral population) from the last time point sequenced were substituted into the /TF sequence, thus generating a modified sequence termed the fixation sequence.</p><p>Identification of MHC Class I restricted epitopes (9–10 amino acids) was performed by analysis of both HCV /TF and fixation sequences in conjunction with MHC Class I genotyping to predict epitopes and then compared with previous experimentally confirmed epitopes from the Immune Epitope Data Base (IEDB [<ext-link ext-link-type="uri" xlink:href="https://www.iedb.org/">https://www.iedb.org/</ext-link>]). This resulted in each prediction list containing at least 10,000 epitope predictions.</p><p>Due to the large number of epitopes and the lack of available PBMCs, a bioinformatics pipeline, iedb_tool, was developed in Python 2.7 to identify a subset of epitopes for further experimental and bioinformatics analyses. This software package is freely available and can be downloaded at: <ext-link ext-link-type="uri" xlink:href="https://github.com/PrestonLeung/IEDBTool2">https://github.com/PrestonLeung/IEDBTool2</ext-link> (copy archived at <xref ref-type="bibr" rid="bib35">Preston, 2025</xref>). The predicted epitopes generated from IEDB were downloaded in plain text format and parsed into <italic>iedb_predictionParser.py</italic> with options <italic>-lower 100.0</italic> to extract relevant subject information (HLA genotypes, predicted epitope sequence, start and end positions of the epitope sequence). The predicted data set was then used with the experimentally validated epitopes from IEDB. This step generated a categorized list of ranked epitopes for which predicted epitopes and HLA-I typing for each subject were matched with experimentally validated epitopes. An 80% homology threshold was set to facilitate small differences between the autologous epitope sequence and those that were previously reported from the IEDB database.</p><p>We prioritized epitopes that matched the HLA allele of the subject and classified these into three categories. Category 1 included epitopes for each subject from which the mutated variant was no longer predicted to be recognized, indicating a potential escape variant. Category 2 included epitopes from those that underwent escape, but the variant was still predicted to be recognized by CD8 +T cells and category 3 included epitopes that did not mutate during infection. A threshold of 10th percentile ranking or higher was used as a cutoff for epitope selection. For categories 2 and 3, we selected a maximum of 10 epitopes due to limitations in PBMC samples. An upper limit of 100 epitopes was set for each subject to account for the total PBMCs available for each time point in the ELISpot matrix testing approach (see below). If the above criteria gave a total number of epitopes less than 40, then epitopes from categories 2 and 3 were searched with a lowered threshold of 50th percentile ranking or higher to increase the sample size to at least 40. This refined list of ranked epitopes we refer to throughout the manuscript as “potential epitopes”.</p></sec><sec id="s4-4"><title>IFN-γ ELISPOT validation</title><p>Potential epitopes generated above were analyzed using matrix IFN-γ ELISPOT assays as previously described (<xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>). While the ELISpot assay detects responses from both CD4 and CD8 T cells, our peptide design (9-10mers) is strongly biased toward CD8 T-cell detection. We have therefore interpreted ELISpot responses primarily in terms of CD8 T-cell activity. Briefly, peptides were synthesized by Mimotopes Australia and used in autologous CD8 +T cell ELISpot assays in pools of ≤5 peptides per well in a matrix format. The peptides were pooled such that any two wells would only have one common peptide, and each peptide was tested in at least two separate wells.</p><p>As previously described by us (<xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>), PBMC were added to a 96-well ELISpot plate (MAIPS; Millipore, USA) precoated with gamma interferon (IFN-γ; Mabtech, Sweden) at a concentration of 150,000 cells per well and incubated overnight with peptides (final concentration of 10 µg/ml). Plates were read and analyzed using an AID plate reader (Autoimmun Diagnostika GmbH, Germany). A peptide/well was concluded to be a positive if it demonstrated an interferon-γ (IFN-γ) response ≥25 spot-forming units per million cells (SFU/million) and a negative control count of zero. A confirmation experiment using the IFN-γ ELISpot assay was conducted for individual positive peptides using one peptide per well in a concentration of 200,000 cells per well. At least one well per study subject was allocated as a positive control (anti-CD3 antibody; Mabtech, Sweden), and three wells were used as negative controls. Background was defined as the mean plus 3 standard deviations of the number of spots counted across the three negative controls.</p></sec><sec id="s4-5"><title>Estimating the rate of CD8+ T-cell epitope escape</title><p>The estimation of the rate of CD8 +T cell epitope escape was performed as previously described (<xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>). Briefly, the kinetics of CD8 +T cell escape was estimated with a simple population dynamics model (<xref ref-type="bibr" rid="bib6">Bull et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Cai et al., 2022</xref>; <xref ref-type="bibr" rid="bib1">Asquith et al., 2006</xref>). The model predicts that the frequency of the escape variant <italic>f</italic>(<italic>t</italic>) is: <inline-formula><alternatives><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>k</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math><tex-math id="inft1">\begin{document}$f(t)=f_0/f_0+(1-f_0)e^{-kt}$\end{document}</tex-math></alternatives></inline-formula>, where k is the rate of escape and it is assumed that the escape variant is present at a low frequency beyond the range of detection during the initial phase of time (t) at zero, and its frequency is given by <italic>f</italic><sub><italic>0</italic></sub>. The escape variant was defined as any observed mutations away from the wild-type sequence that consequently becomes fixed in the population. Therefore, the frequency of the escape variant at individual longitudinal time points was the total frequencies of each epitope carrying the escape mutation regardless of the other amino acid positions. In some cases where the escape variant was not observed in the earlier time points, an estimate of <italic>1/(n+1</italic>) replaces a frequency of 0, where n is the average coverage of the corresponding time point from the deep sequencing data. This model was used to estimate the rate of escape only in those cases with experimental evidence (ELISpot data generated in this study) of CD8 +T-cell-driven immune escape. Estimates were performed in R usin ag non-linear least-squares approach for non-linear models (<xref ref-type="bibr" rid="bib37">R Development Core Team, 2012</xref>).</p></sec><sec id="s4-6"><title>Estimating survival fitness of viral variants</title><p>The model used for estimating viral fitness has been previously described by <xref ref-type="bibr" rid="bib18">Hart and Ferguson, 2015</xref>. Briefly, the original approach used HCV subtype 1 a sequences to generate the model for the NS5B protein region. To update the model for other regions (NS3 and NS2) as well as other HCV subtypes in this study, subtype 1b and subtype 3 a sequences were extracted from the Los Alamos National Laboratory HCV database. An intrinsic fitness model was first generated for each subtype for NS5B, NS3, and NS2 region of the HCV polyprotein. Then, using longitudinally sequenced data from patients chronically infected with HCV as well as clinically documented immune escape to describe high viral fitness variants, we generated estimates of the viral fitness for subjects chronically infected with HCV in our cohort. This was performed on each viral variant reconstructed by QuasiRecomb as previously described (<xref ref-type="bibr" rid="bib18">Hart and Ferguson, 2015</xref>; <xref ref-type="bibr" rid="bib13">Ferguson et al., 2013</xref>; <xref ref-type="bibr" rid="bib3">Barton et al., 2016</xref>). Specifically, haplotype reconstruction was performed longitudinally for each subject in a region of approximately 600 amino acids surrounding the experimentally confirmed CD8 +T cell epitopes. The fitness landscape inference is obtained by estimating the parameter of a function <inline-formula><alternatives><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mover><mml:mi>z</mml:mi><mml:mo stretchy="false">→</mml:mo></mml:mover><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math><tex-math id="inft2">\begin{document}$E\left (\overset{\rightarrow }{z}\right)$\end{document}</tex-math></alternatives></inline-formula> representing the energy of the viral population and with <inline-formula><alternatives><mml:math id="inf3"><mml:mi>P</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>z</mml:mi></mml:mrow><mml:mo>→</mml:mo></mml:mover></mml:mrow></mml:mfenced></mml:math><tex-math id="inft3">\begin{document}$P\left (\overset{\rightarrow }{z}\right)$\end{document}</tex-math></alternatives></inline-formula>:<disp-formula id="equ1"><alternatives><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mover><mml:mi>z</mml:mi><mml:mo stretchy="false">→</mml:mo></mml:mover><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mover><mml:mi>z</mml:mi><mml:mo stretchy="false">→</mml:mo></mml:mover><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:mi>z</mml:mi></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:math><tex-math id="t1">\begin{document}$$\displaystyle P\left (\overset{\rightarrow }{z}\right)= \frac{e^{-E\left (\overset{\rightarrow }{z}\right)}}{z},$$\end{document}</tex-math></alternatives></disp-formula><disp-formula id="equ2"><alternatives><mml:math id="m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mover><mml:mi>z</mml:mi><mml:mo stretchy="false">→</mml:mo></mml:mover><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>h</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>J</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t2">\begin{document}$$\displaystyle  E\left (\overset{\rightarrow }{z}\right)=\ \sum \limits_{i=1}^{m}h_{i}\left (z_{i}\right)+\sum \limits_{i=1}^{m}\sum \limits_{j=i+1}^{m}J_{ij}\left (z_{i},z_{j}\right)$$\end{document}</tex-math></alternatives></disp-formula></p><p>where <inline-formula><alternatives><mml:math id="inf4"><mml:mover accent="true"><mml:mrow><mml:mi>z</mml:mi></mml:mrow><mml:mo>→</mml:mo></mml:mover></mml:math><tex-math id="inft4">\begin{document}$\overset{\rightarrow }{z}$\end{document}</tex-math></alternatives></inline-formula> is the peptide sequence of length <italic>m</italic> such that <inline-formula><alternatives><mml:math id="inf5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mover><mml:mi>z</mml:mi><mml:mo stretchy="false">→</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:msub><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math><tex-math id="inft5">\begin{document}$\overset{\rightarrow}{z}=\left \{z_{1,}z_{2},\ldots z_{m}\right\}$\end{document}</tex-math></alternatives></inline-formula> describes individual amino acids in <inline-formula><alternatives><mml:math id="inf6"><mml:mover accent="true"><mml:mrow><mml:mi>z</mml:mi></mml:mrow><mml:mo>→</mml:mo></mml:mover></mml:math><tex-math id="inft6">\begin{document}$\overset{\rightarrow }{z}$\end{document}</tex-math></alternatives></inline-formula>. <inline-formula><alternatives><mml:math id="inf7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mover><mml:mi>z</mml:mi><mml:mo stretchy="false">→</mml:mo></mml:mover><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math><tex-math id="inft7">\begin{document}$P\left (\overset{\rightarrow }{z}\right)$\end{document}</tex-math></alternatives></inline-formula> is the prevalence fitness taken under the assumption that the frequently occurring variants represent the fitter strain (i.e. the common circulating virus, in this case the original T/F virus), and this mathematically defined fitness correlates positively to the actual viral fitness <inline-formula><alternatives><mml:math id="inf8"><mml:mi>f</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>z</mml:mi></mml:mrow><mml:mo>→</mml:mo></mml:mover></mml:mrow></mml:mfenced></mml:math><tex-math id="inft8">\begin{document}$f\left (\overset{\rightarrow }{z}\right)$\end{document}</tex-math></alternatives></inline-formula> (<xref ref-type="bibr" rid="bib13">Ferguson et al., 2013</xref>). <inline-formula><alternatives><mml:math id="inf9"><mml:mi>E</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>z</mml:mi></mml:mrow><mml:mo>→</mml:mo></mml:mover></mml:mrow></mml:mfenced></mml:math><tex-math id="inft9">\begin{document}$E\left (\overset{\rightarrow }{z}\right)$\end{document}</tex-math></alternatives></inline-formula> is the ‘energy’ of peptide <inline-formula><alternatives><mml:math id="inf10"><mml:mover accent="true"><mml:mrow><mml:mi>z</mml:mi></mml:mrow><mml:mo>→</mml:mo></mml:mover></mml:math><tex-math id="inft10">\begin{document}$\overset{\rightarrow }{z}$\end{document}</tex-math></alternatives></inline-formula> a pseudo measurement for fitness, and <italic>z</italic> is a normalization factor described in the following equation.<disp-formula id="equ3"><alternatives><mml:math id="m3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi><mml:mo>=</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:msub></mml:munder><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mover><mml:mi>z</mml:mi><mml:mo stretchy="false">→</mml:mo></mml:mover><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t3">\begin{document}$$\displaystyle  z= \underset{z_{i=\left \{1,0\right \}}}{\sum }e^{-E\left (\overset{\rightarrow }{z}\right)}$$\end{document}</tex-math></alternatives></disp-formula></p><p>The parameter <inline-formula><alternatives><mml:math id="inf11"><mml:msub><mml:mrow><mml:mi>h</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math><tex-math id="inft11">\begin{document}$h_{i}\left (z_{i}\right)$\end{document}</tex-math></alternatives></inline-formula> is the contribution of energy of the single amino acid at position <italic>i</italic> of <inline-formula><alternatives><mml:math id="inf12"><mml:mover accent="true"><mml:mrow><mml:mi>z</mml:mi></mml:mrow><mml:mo>→</mml:mo></mml:mover></mml:math><tex-math id="inft12">\begin{document}$\overset{\rightarrow }{z}$\end{document}</tex-math></alternatives></inline-formula>. <inline-formula><alternatives><mml:math id="inf13"><mml:msub><mml:mrow><mml:mi>J</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>z</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math><tex-math id="inft13">\begin{document}$J_{ij}\left (z_{i},z_{j}\right)$\end{document}</tex-math></alternatives></inline-formula> specifies the energy contribution associated with pairwise interactions between two amino acids in <inline-formula><alternatives><mml:math id="inf14"><mml:mover accent="true"><mml:mrow><mml:mi>z</mml:mi></mml:mrow><mml:mo>→</mml:mo></mml:mover></mml:math><tex-math id="inft14">\begin{document}$\overset{\rightarrow }{z}$\end{document}</tex-math></alternatives></inline-formula> at positions <italic>i</italic> and <italic>j</italic>. Under the model assumptions, the association between measurement of energy and fitness estimate showed a negative correlation where minimal <inline-formula><alternatives><mml:math id="inf15"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mover><mml:mi>z</mml:mi><mml:mo stretchy="false">→</mml:mo></mml:mover><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math><tex-math id="inft15">\begin{document}$E\left (\overset{\rightarrow}{z}\right)$\end{document}</tex-math></alternatives></inline-formula> maximizes the logarithm of the viral fitness <inline-formula><alternatives><mml:math id="inf16"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">log</mml:mi></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mi>f</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>z</mml:mi></mml:mrow><mml:mo>→</mml:mo></mml:mover></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math><tex-math id="inft16">\begin{document}$\log \left (f\left (\overset{\rightarrow }{z}\right)\right)$\end{document}</tex-math></alternatives></inline-formula> (<xref ref-type="bibr" rid="bib18">Hart and Ferguson, 2015</xref>).</p><p>A relative fitness estimate was also calculated for reconstructed haplotypes by normalizing individual fitness estimates with respect to the fitness of the haplotype corresponding to the T/F variant such that the T/F variant will have a fitness of 1.000. These values were used to represent the viral fitness of individual haplotypes to infer viral evolution dynamics with respect to the T/F virus.</p><p>This analysis was used to quantify the selection exerted by the host cytotoxic T cell response in driving the evolution of the T/F virus. The analysis also showed the role of specific co-evolving mutations and the identification of epistatic interactions that may determine the evolution of viral fitness and the overall success of the infection.</p></sec><sec id="s4-7"><title>Cell lines</title><p>Human cell lines, Lenti-XTM 293 T (Takara, Mountain View, CA, USA) and Huh7.5 (Apath, New York, NY, USA) were cultured at 37  °C in a humidified atmosphere containing 5% CO₂, using High Glucose Dulbecco’s Modified Eagle Medium (HG-DMEM; Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS; Gibco). These cells were authenticated by STR profiling and were confirmed to be mycoplasma negative.</p></sec><sec id="s4-8"><title>HCVpp production, infection, and neutralization</title><p>As previously described by us, E1E2 glycoproteins were cloned and co-transfected with MLV gag/pol and luciferase vectors in Lenti-X 293 T -cells to produce HCV-pseudo-particles (pp) (<xref ref-type="bibr" rid="bib48">Walker et al., 2020</xref>; <xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>). Briefly, neutralization assays were performed by incubating HCVpp with heat-inactivated plasma for one hour at 37  °C. This mixture was applied directly to Huh-7.5 hepatoma cells (Apath, L.L.C, New York, NY, USA), and incubated for 72 hr after which luciferase activity was measured (<xref ref-type="bibr" rid="bib47">Walker et al., 2019</xref>). Neutralization of HCVpp was calculated using the formula: % inhibition  = 1 − (inhibited activity)/(‘normal’ activity)×100, after subtraction of negative control (pseudo-particle generated without glycoproteins) RLU, where normal activity is HCVpp incubated with plasma from a healthy donor. The 50% ID50 titer was calculated as the nAb concentration that caused a 50% reduction in RLU for each plasma/HCVpp combination tested in neutralization. All samples were also tested for neutralizing activity on control pseudo-particle VSV-G, to determine that nAbs were HCV E1E2 specific. All data were fitted using non-linear regression plots (GraphPad, Prism).</p></sec><sec id="s4-9"><title>Data visualization and statistical analysis</title><p>Data visualization for CD8 +T cell analyses was performed using ggplot2 package (<xref ref-type="bibr" rid="bib50">Wickham, 2016</xref>) in R (<xref ref-type="bibr" rid="bib37">R Development Core Team, 2012</xref>). Visualization of viral fitness estimates and longitudinal neutralization and CD8 +T cell data was performed using GraphPad Prism version 10.0 for Windows, GraphPad Software, La Jolla California USA (<ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link>). As were comparisons of timing of nAb and CD8 +T cell responses where Wilcoxon matched-pairs signed rank tests were performed. Sequence alignments for highlighter plots were performed on the variants generated here using Geneious Prime 2023 (<ext-link ext-link-type="uri" xlink:href="https://www.geneious.com">https://www.geneious.com</ext-link>).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Formal analysis, Supervision, Investigation, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Human research ethics approvals were obtained from Human Research Ethics Committees of Justice Health (reference number GEN 31/05), New South Wales Department of Corrective Services (05/0884), and the University of New South Wales (05094, 08081), all located in Sydney, Australia. Written informed consent was obtained from the participants. All methods were performed in accordance with the relevant guidelines and regulations.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-102232-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Summary of epitope selection and (IFN-γ) ELISPOT assay responses in subjects who cleared infection.</title></caption><media xlink:href="elife-102232-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Summary of epitope selection and positive (IFN-γ) ELISPOT assay responses in subjects who developed chronic infection.</title></caption><media xlink:href="elife-102232-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Subject 300023 relative fitness estimate, co-occurring mutations and frequency of occurrence for each reconstructed haplotype.</title></caption><media xlink:href="elife-102232-supp3-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Subject 300240 relative fitness estimate, co-occurring mutations and frequency of occurrence for each reconstructed haplotype.</title></caption><media xlink:href="elife-102232-supp4-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Subject 300256 relative fitness estimate, co-occurring mutations and frequency of occurrence for each reconstructed haplotype.</title></caption><media xlink:href="elife-102232-supp5-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Subject HOKD0485FX relative fitness estimate, co-occurring mutations and frequency of occurrence for each reconstructed haplotype.</title></caption><media xlink:href="elife-102232-supp6-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1–5. The code is freely available and can be downloaded at <ext-link ext-link-type="uri" xlink:href="https://github.com/PrestonLeung/IEDBTool2">GitHub</ext-link> (copy archived at <xref ref-type="bibr" rid="bib35">Preston, 2025</xref>). Single-cell RNA seq data are available on accession number GSE196330. All the single-cell RNA-seq data are deposited with GSE196330.</p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset1"><person-group person-group-type="author"><name><surname>Luciani</surname><given-names>F</given-names></name><name><surname>Cai</surname><given-names>C</given-names></name><name><surname>Samir</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Single cell multi-omics reveals early elevated function and multiple fates within human progenitors of exhausted CD8+ T cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE196330">GSE196330</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We acknowledge Gregory R Hart and Prof. Andrew L Ferguson for their assistance with the fitness models.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asquith</surname><given-names>B</given-names></name><name><surname>Edwards</surname><given-names>CTT</given-names></name><name><surname>Lipsitch</surname><given-names>M</given-names></name><name><surname>McLean</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo</article-title><source>PLOS Biology</source><volume>4</volume><elocation-id>e90</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.0040090</pub-id><pub-id pub-id-type="pmid">16515366</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurora</surname><given-names>R</given-names></name><name><surname>Donlin</surname><given-names>MJ</given-names></name><name><surname>Cannon</surname><given-names>NA</given-names></name><name><surname>Tavis</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans</article-title><source>The Journal of Clinical Investigation</source><volume>119</volume><fpage>225</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1172/JCI37085</pub-id><pub-id pub-id-type="pmid">19104147</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>JP</given-names></name><name><surname>Goonetilleke</surname><given-names>N</given-names></name><name><surname>Butler</surname><given-names>TC</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><name><surname>McMichael</surname><given-names>AJ</given-names></name><name><surname>Chakraborty</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>11660</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms11660</pub-id><pub-id pub-id-type="pmid">27212475</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartosch</surname><given-names>B</given-names></name><name><surname>Dubuisson</surname><given-names>J</given-names></name><name><surname>Cosset</surname><given-names>F-L</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Infectious hepatitis C virus pseudo-particles containing functional E1–E2 envelope protein complexes</article-title><source>The Journal of Experimental Medicine</source><volume>197</volume><fpage>633</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1084/jem.20021756</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bull</surname><given-names>RA</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name><name><surname>McElroy</surname><given-names>K</given-names></name><name><surname>Gaudieri</surname><given-names>S</given-names></name><name><surname>Pham</surname><given-names>ST</given-names></name><name><surname>Chopra</surname><given-names>A</given-names></name><name><surname>Cameron</surname><given-names>B</given-names></name><name><surname>Maher</surname><given-names>L</given-names></name><name><surname>Dore</surname><given-names>GJ</given-names></name><name><surname>White</surname><given-names>PA</given-names></name><name><surname>Lloyd</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection</article-title><source>PLOS Pathogens</source><volume>7</volume><elocation-id>e1002243</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1002243</pub-id><pub-id pub-id-type="pmid">21912520</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bull</surname><given-names>RA</given-names></name><name><surname>Leung</surname><given-names>P</given-names></name><name><surname>Gaudieri</surname><given-names>S</given-names></name><name><surname>Deshpande</surname><given-names>P</given-names></name><name><surname>Cameron</surname><given-names>B</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Chopra</surname><given-names>A</given-names></name><name><surname>Lloyd</surname><given-names>AR</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Transmitted/founder viruses rapidly escape from CD8+ T cell responses in acute hepatitis C virus infection</article-title><source>Journal of Virology</source><volume>89</volume><fpage>5478</fpage><lpage>5490</lpage><pub-id pub-id-type="doi">10.1128/JVI.03717-14</pub-id><pub-id pub-id-type="pmid">25740982</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bull</surname><given-names>RA</given-names></name><name><surname>Eltahla</surname><given-names>AA</given-names></name><name><surname>Rodrigo</surname><given-names>C</given-names></name><name><surname>Koekkoek</surname><given-names>SM</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Pirozyan</surname><given-names>MR</given-names></name><name><surname>Betz-Stablein</surname><given-names>B</given-names></name><name><surname>Toepfer</surname><given-names>A</given-names></name><name><surname>Laird</surname><given-names>M</given-names></name><name><surname>Oh</surname><given-names>S</given-names></name><name><surname>Heiner</surname><given-names>C</given-names></name><name><surname>Maher</surname><given-names>L</given-names></name><name><surname>Schinkel</surname><given-names>J</given-names></name><name><surname>Lloyd</surname><given-names>AR</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A method for near full-length amplification and sequencing for six hepatitis C virus genotypes</article-title><source>BMC Genomics</source><volume>17</volume><elocation-id>247</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-016-2575-8</pub-id><pub-id pub-id-type="pmid">26988550</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>C</given-names></name><name><surname>Samir</surname><given-names>J</given-names></name><name><surname>Pirozyan</surname><given-names>MR</given-names></name><name><surname>Adikari</surname><given-names>TN</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Leung</surname><given-names>P</given-names></name><name><surname>Hughes</surname><given-names>B</given-names></name><name><surname>Van der Byl</surname><given-names>W</given-names></name><name><surname>Rizzetto</surname><given-names>S</given-names></name><name><surname>Elthala</surname><given-names>A</given-names></name><name><surname>Keoshkerian</surname><given-names>E</given-names></name><name><surname>Palgen</surname><given-names>JL</given-names></name><name><surname>Peters</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>THO</given-names></name><name><surname>Louie</surname><given-names>R</given-names></name><name><surname>Kedzierska</surname><given-names>K</given-names></name><name><surname>Gaudieri</surname><given-names>S</given-names></name><name><surname>Bull</surname><given-names>RA</given-names></name><name><surname>Lloyd</surname><given-names>AR</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Identification of human progenitors of exhausted CD8<sup>+</sup> T cells associated with elevated IFN-γ response in early phase of viral infection</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>7543</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-35281-7</pub-id><pub-id pub-id-type="pmid">36477661</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campo</surname><given-names>DS</given-names></name><name><surname>Dimitrova</surname><given-names>Z</given-names></name><name><surname>Mitchell</surname><given-names>RJ</given-names></name><name><surname>Lara</surname><given-names>J</given-names></name><name><surname>Khudyakov</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Coordinated evolution of the hepatitis C virus</article-title><source>PNAS</source><volume>105</volume><fpage>9685</fpage><lpage>9690</lpage><pub-id pub-id-type="doi">10.1073/pnas.0801774105</pub-id><pub-id pub-id-type="pmid">18621679</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campo</surname><given-names>DS</given-names></name><name><surname>Dimitrova</surname><given-names>Z</given-names></name><name><surname>Yamasaki</surname><given-names>L</given-names></name><name><surname>Skums</surname><given-names>P</given-names></name><name><surname>Lau</surname><given-names>DT</given-names></name><name><surname>Vaughan</surname><given-names>G</given-names></name><name><surname>Forbi</surname><given-names>JC</given-names></name><name><surname>Teo</surname><given-names>C-G</given-names></name><name><surname>Khudyakov</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Next-generation sequencing reveals large connected networks of intra-host HCV variants</article-title><source>BMC Genomics</source><volume>15 Suppl 5</volume><elocation-id>S4</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2164-15-S5-S4</pub-id><pub-id pub-id-type="pmid">25081811</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>EB</given-names></name><name><surname>Hajarizadeh</surname><given-names>B</given-names></name><name><surname>Bretana</surname><given-names>NA</given-names></name><name><surname>Amin</surname><given-names>J</given-names></name><name><surname>Betz-Stablein</surname><given-names>B</given-names></name><name><surname>Dore</surname><given-names>GJ</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name><name><surname>Teutsch</surname><given-names>S</given-names></name><name><surname>Dolan</surname><given-names>K</given-names></name><name><surname>Lloyd</surname><given-names>AR</given-names></name><name><surname>Grebely</surname><given-names>J</given-names></name><collab>HITS-p investigators</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study</article-title><source>Journal of Viral Hepatitis</source><volume>24</volume><fpage>733</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1111/jvh.12701</pub-id><pub-id pub-id-type="pmid">28256027</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowd</surname><given-names>KA</given-names></name><name><surname>Netski</surname><given-names>DM</given-names></name><name><surname>Wang</surname><given-names>XH</given-names></name><name><surname>Cox</surname><given-names>AL</given-names></name><name><surname>Ray</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus</article-title><source>Gastroenterology</source><volume>136</volume><fpage>2377</fpage><lpage>2386</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.02.080</pub-id><pub-id pub-id-type="pmid">19303013</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>AL</given-names></name><name><surname>Mann</surname><given-names>JK</given-names></name><name><surname>Omarjee</surname><given-names>S</given-names></name><name><surname>Ndung’u</surname><given-names>T</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><name><surname>Chakraborty</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design</article-title><source>Immunity</source><volume>38</volume><fpage>606</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.11.022</pub-id><pub-id pub-id-type="pmid">23521886</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frumento</surname><given-names>N</given-names></name><name><surname>Sinnis-Bourozikas</surname><given-names>A</given-names></name><name><surname>Paul</surname><given-names>HT</given-names></name><name><surname>Stavrakis</surname><given-names>G</given-names></name><name><surname>Zahid</surname><given-names>MN</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Ray</surname><given-names>SC</given-names></name><name><surname>Flyak</surname><given-names>AI</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Cox</surname><given-names>AL</given-names></name><name><surname>Bailey</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection</article-title><source>Immunity</source><volume>57</volume><fpage>40</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2023.12.004</pub-id><pub-id pub-id-type="pmid">38171362</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuerst</surname><given-names>TR</given-names></name><name><surname>Pierce</surname><given-names>BG</given-names></name><name><surname>Keck</surname><given-names>ZY</given-names></name><name><surname>Foung</surname><given-names>SKH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Designing a B cell-based vaccine against a highly variable hepatitis C virus</article-title><source>Frontiers in Microbiology</source><volume>8</volume><elocation-id>2692</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2017.02692</pub-id><pub-id pub-id-type="pmid">29379486</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaudieri</surname><given-names>S</given-names></name><name><surname>Rauch</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>LP</given-names></name><name><surname>Freitas</surname><given-names>E</given-names></name><name><surname>Herrmann</surname><given-names>S</given-names></name><name><surname>Jeffrey</surname><given-names>G</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name><name><surname>Pfafferott</surname><given-names>K</given-names></name><name><surname>Naidoo</surname><given-names>K</given-names></name><name><surname>Chapman</surname><given-names>R</given-names></name><name><surname>Battegay</surname><given-names>M</given-names></name><name><surname>Weber</surname><given-names>R</given-names></name><name><surname>Telenti</surname><given-names>A</given-names></name><name><surname>Furrer</surname><given-names>H</given-names></name><name><surname>James</surname><given-names>I</given-names></name><name><surname>Lucas</surname><given-names>M</given-names></name><name><surname>Mallal</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection</article-title><source>Journal of Virology</source><volume>80</volume><fpage>11094</fpage><lpage>11104</lpage><pub-id pub-id-type="doi">10.1128/JVI.00912-06</pub-id><pub-id pub-id-type="pmid">17071929</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glynn</surname><given-names>SA</given-names></name><name><surname>Wright</surname><given-names>DJ</given-names></name><name><surname>Kleinman</surname><given-names>SH</given-names></name><name><surname>Hirschkorn</surname><given-names>D</given-names></name><name><surname>Tu</surname><given-names>Y</given-names></name><name><surname>Heldebrant</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Giachetti</surname><given-names>C</given-names></name><name><surname>Gallarda</surname><given-names>J</given-names></name><name><surname>Busch</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Dynamics of viremia in early hepatitis C virus infection</article-title><source>Transfusion</source><volume>45</volume><fpage>994</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2005.04390.x</pub-id><pub-id pub-id-type="pmid">15934999</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>GR</given-names></name><name><surname>Ferguson</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Empirical fitness models for hepatitis C virus immunogen design</article-title><source>Physical Biology</source><volume>12</volume><elocation-id>066006</elocation-id><pub-id pub-id-type="doi">10.1088/1478-3975/12/6/066006</pub-id><pub-id pub-id-type="pmid">26599153</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedskog</surname><given-names>C</given-names></name><name><surname>Parhy</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>S</given-names></name><name><surname>Zeuzem</surname><given-names>S</given-names></name><name><surname>Moreno</surname><given-names>C</given-names></name><name><surname>Shafran</surname><given-names>SD</given-names></name><name><surname>Borgia</surname><given-names>SM</given-names></name><name><surname>Asselah</surname><given-names>T</given-names></name><name><surname>Alric</surname><given-names>L</given-names></name><name><surname>Abergel</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>J-J</given-names></name><name><surname>Collier</surname><given-names>J</given-names></name><name><surname>Kapoor</surname><given-names>D</given-names></name><name><surname>Hyland</surname><given-names>RH</given-names></name><name><surname>Simmonds</surname><given-names>P</given-names></name><name><surname>Mo</surname><given-names>H</given-names></name><name><surname>Svarovskaia</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification of 19 novel hepatitis C Virus subtypes-further expanding HCV classification</article-title><source>Open Forum Infectious Diseases</source><volume>6</volume><elocation-id>ofz076</elocation-id><pub-id pub-id-type="doi">10.1093/ofid/ofz076</pub-id><pub-id pub-id-type="pmid">30949527</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kantzanou</surname><given-names>M</given-names></name><name><surname>Lucas</surname><given-names>M</given-names></name><name><surname>Barnes</surname><given-names>E</given-names></name><name><surname>Komatsu</surname><given-names>H</given-names></name><name><surname>Dusheiko</surname><given-names>G</given-names></name><name><surname>Ward</surname><given-names>S</given-names></name><name><surname>Harcourt</surname><given-names>G</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Viral escape and T cell exhaustion in hepatitis C virus infection analysed using Class I peptide tetramers</article-title><source>Immunology Letters</source><volume>85</volume><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/s0165-2478(02)00224-9</pub-id><pub-id pub-id-type="pmid">12527224</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keele</surname><given-names>BF</given-names></name><name><surname>Giorgi</surname><given-names>EE</given-names></name><name><surname>Salazar-Gonzalez</surname><given-names>JF</given-names></name><name><surname>Decker</surname><given-names>JM</given-names></name><name><surname>Pham</surname><given-names>KT</given-names></name><name><surname>Salazar</surname><given-names>MG</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Grayson</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Kirchherr</surname><given-names>JL</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name><name><surname>Ping</surname><given-names>LH</given-names></name><name><surname>Swanstrom</surname><given-names>R</given-names></name><name><surname>Tomaras</surname><given-names>GD</given-names></name><name><surname>Blattner</surname><given-names>WA</given-names></name><name><surname>Goepfert</surname><given-names>PA</given-names></name><name><surname>Kilby</surname><given-names>JM</given-names></name><name><surname>Saag</surname><given-names>MS</given-names></name><name><surname>Delwart</surname><given-names>EL</given-names></name><name><surname>Busch</surname><given-names>MP</given-names></name><name><surname>Cohen</surname><given-names>MS</given-names></name><name><surname>Montefiori</surname><given-names>DC</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Gaschen</surname><given-names>B</given-names></name><name><surname>Athreya</surname><given-names>GS</given-names></name><name><surname>Lee</surname><given-names>HY</given-names></name><name><surname>Wood</surname><given-names>N</given-names></name><name><surname>Seoighe</surname><given-names>C</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Bhattacharya</surname><given-names>T</given-names></name><name><surname>Korber</surname><given-names>BT</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection</article-title><source>PNAS</source><volume>105</volume><fpage>7552</fpage><lpage>7557</lpage><pub-id pub-id-type="doi">10.1073/pnas.0802203105</pub-id><pub-id pub-id-type="pmid">18490657</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuntzen</surname><given-names>T</given-names></name><name><surname>Timm</surname><given-names>J</given-names></name><name><surname>Berical</surname><given-names>A</given-names></name><name><surname>Lewis-Ximenez</surname><given-names>LL</given-names></name><name><surname>Jones</surname><given-names>A</given-names></name><name><surname>Nolan</surname><given-names>B</given-names></name><name><surname>Schulze zur Wiesch</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Schneidewind</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>AY</given-names></name><name><surname>Chung</surname><given-names>RT</given-names></name><name><surname>Lauer</surname><given-names>GM</given-names></name><name><surname>Allen</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Viral sequence evolution in acute hepatitis C virus infection</article-title><source>Journal of Virology</source><volume>81</volume><fpage>11658</fpage><lpage>11668</lpage><pub-id pub-id-type="doi">10.1128/JVI.00995-07</pub-id><pub-id pub-id-type="pmid">17699568</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanini</surname><given-names>S</given-names></name><name><surname>Easterbrook</surname><given-names>PJ</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Ippolito</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hepatitis C: global epidemiology and strategies for control</article-title><source>Clinical Microbiology and Infection</source><volume>22</volume><fpage>833</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2016.07.035</pub-id><pub-id pub-id-type="pmid">27521803</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavanchy</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The global burden of hepatitis C</article-title><source>Liver International</source><volume>1</volume><fpage>74</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2008.01934.x</pub-id><pub-id pub-id-type="pmid">19207969</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavillette</surname><given-names>D</given-names></name><name><surname>Tarr</surname><given-names>AW</given-names></name><name><surname>Voisset</surname><given-names>C</given-names></name><name><surname>Donot</surname><given-names>P</given-names></name><name><surname>Bartosch</surname><given-names>B</given-names></name><name><surname>Bain</surname><given-names>C</given-names></name><name><surname>Patel</surname><given-names>AH</given-names></name><name><surname>Dubuisson</surname><given-names>J</given-names></name><name><surname>Ball</surname><given-names>JK</given-names></name><name><surname>Cosset</surname><given-names>F-L</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus</article-title><source>Hepatology</source><volume>41</volume><fpage>265</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1002/hep.20542</pub-id><pub-id pub-id-type="pmid">15660396</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>P</given-names></name><name><surname>Bull</surname><given-names>R</given-names></name><name><surname>Lloyd</surname><given-names>A</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A bioinformatics pipeline for the analyses of viral escape dynamics and host immune responses during an infection</article-title><source>BioMed Research International</source><volume>2014</volume><elocation-id>264519</elocation-id><pub-id pub-id-type="doi">10.1155/2014/264519</pub-id><pub-id pub-id-type="pmid">25013771</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Stoddard</surname><given-names>MB</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Giorgi</surname><given-names>EE</given-names></name><name><surname>Blair</surname><given-names>LM</given-names></name><name><surname>Learn</surname><given-names>GH</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Alter</surname><given-names>HJ</given-names></name><name><surname>Busch</surname><given-names>MP</given-names></name><name><surname>Fierer</surname><given-names>DS</given-names></name><name><surname>Ribeiro</surname><given-names>RM</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Bhattacharya</surname><given-names>T</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Single-genome sequencing of hepatitis C virus in donor-recipient pairs distinguishes modes and models of virus transmission and early diversification</article-title><source>Journal of Virology</source><volume>90</volume><fpage>152</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1128/JVI.02156-15</pub-id><pub-id pub-id-type="pmid">26468546</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>MKP</given-names></name><name><surname>Hawkins</surname><given-names>N</given-names></name><name><surname>Ritchie</surname><given-names>AJ</given-names></name><name><surname>Ganusov</surname><given-names>VV</given-names></name><name><surname>Whale</surname><given-names>V</given-names></name><name><surname>Brackenridge</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Pavlicek</surname><given-names>JW</given-names></name><name><surname>Cai</surname><given-names>F</given-names></name><name><surname>Rose-Abrahams</surname><given-names>M</given-names></name><name><surname>Treurnicht</surname><given-names>F</given-names></name><name><surname>Hraber</surname><given-names>P</given-names></name><name><surname>Riou</surname><given-names>C</given-names></name><name><surname>Gray</surname><given-names>C</given-names></name><name><surname>Ferrari</surname><given-names>G</given-names></name><name><surname>Tanner</surname><given-names>R</given-names></name><name><surname>Ping</surname><given-names>LH</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name><name><surname>Swanstrom</surname><given-names>R</given-names></name><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Karim</surname><given-names>SSA</given-names></name><name><surname>Haynes</surname><given-names>B</given-names></name><name><surname>Borrow</surname><given-names>P</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Williamson</surname><given-names>C</given-names></name><name><surname>Korber</surname><given-names>BT</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Self</surname><given-names>S</given-names></name><name><surname>McMichael</surname><given-names>A</given-names></name><name><surname>Goonetilleke</surname><given-names>N</given-names></name><collab>CHAVI Core B</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Vertical T cell immunodominance and epitope entropy determine HIV-1 escape</article-title><source>The Journal of Clinical Investigation</source><volume>123</volume><fpage>380</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1172/JCI65330</pub-id><pub-id pub-id-type="pmid">23221345</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Micallef</surname><given-names>JM</given-names></name><name><surname>Kaldor</surname><given-names>JM</given-names></name><name><surname>Dore</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies</article-title><source>Journal of Viral Hepatitis</source><volume>13</volume><fpage>34</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2893.2005.00651.x</pub-id><pub-id pub-id-type="pmid">16364080</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>JM</given-names></name><name><surname>Moenne-Loccoz</surname><given-names>R</given-names></name><name><surname>Velay</surname><given-names>A</given-names></name><name><surname>Habersetzer</surname><given-names>F</given-names></name><name><surname>Doffoël</surname><given-names>M</given-names></name><name><surname>Gut</surname><given-names>J-P</given-names></name><name><surname>Fofana</surname><given-names>I</given-names></name><name><surname>Zeisel</surname><given-names>MB</given-names></name><name><surname>Stoll-Keller</surname><given-names>F</given-names></name><name><surname>Baumert</surname><given-names>TF</given-names></name><name><surname>Schvoerer</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e67254</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0067254</pub-id><pub-id pub-id-type="pmid">23840641</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oniangue-Ndza</surname><given-names>C</given-names></name><name><surname>Kuntzen</surname><given-names>T</given-names></name><name><surname>Kemper</surname><given-names>M</given-names></name><name><surname>Berical</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>YE</given-names></name><name><surname>Neumann-Haefelin</surname><given-names>C</given-names></name><name><surname>Foote</surname><given-names>PK</given-names></name><name><surname>Hills-Evans</surname><given-names>K</given-names></name><name><surname>Reyor</surname><given-names>LL</given-names></name><name><surname>Kane</surname><given-names>K</given-names></name><name><surname>Gladden</surname><given-names>AD</given-names></name><name><surname>Bloom</surname><given-names>AK</given-names></name><name><surname>Power</surname><given-names>KA</given-names></name><name><surname>Thimme</surname><given-names>R</given-names></name><name><surname>Lauer</surname><given-names>GM</given-names></name><name><surname>Henn</surname><given-names>MR</given-names></name><name><surname>Kim</surname><given-names>AY</given-names></name><name><surname>Allen</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Compensatory mutations restore the replication defects caused by cytotoxic T lymphocyte escape mutations in hepatitis C virus polymerase</article-title><source>Journal of Virology</source><volume>85</volume><fpage>11883</fpage><lpage>11890</lpage><pub-id pub-id-type="doi">10.1128/JVI.00779-11</pub-id><pub-id pub-id-type="pmid">21880756</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osburn</surname><given-names>WO</given-names></name><name><surname>Snider</surname><given-names>AE</given-names></name><name><surname>Wells</surname><given-names>BL</given-names></name><name><surname>Latanich</surname><given-names>R</given-names></name><name><surname>Bailey</surname><given-names>JR</given-names></name><name><surname>Thomas</surname><given-names>DL</given-names></name><name><surname>Cox</surname><given-names>AL</given-names></name><name><surname>Ray</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses</article-title><source>Hepatology</source><volume>59</volume><fpage>2140</fpage><lpage>2151</lpage><pub-id pub-id-type="doi">10.1002/hep.27013</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>K</given-names></name><name><surname>Melia</surname><given-names>MT</given-names></name><name><surname>Veenhuis</surname><given-names>RT</given-names></name><name><surname>Winter</surname><given-names>M</given-names></name><name><surname>Rousseau</surname><given-names>KE</given-names></name><name><surname>Massaccesi</surname><given-names>G</given-names></name><name><surname>Osburn</surname><given-names>WO</given-names></name><name><surname>Forman</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>E</given-names></name><name><surname>Thornton</surname><given-names>K</given-names></name><name><surname>Wagner</surname><given-names>K</given-names></name><name><surname>Vassilev</surname><given-names>V</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Lum</surname><given-names>PJ</given-names></name><name><surname>Giudice</surname><given-names>LC</given-names></name><name><surname>Stein</surname><given-names>E</given-names></name><name><surname>Asher</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>S</given-names></name><name><surname>Gorman</surname><given-names>R</given-names></name><name><surname>Ghany</surname><given-names>MG</given-names></name><name><surname>Liang</surname><given-names>TJ</given-names></name><name><surname>Wierzbicki</surname><given-names>MR</given-names></name><name><surname>Scarselli</surname><given-names>E</given-names></name><name><surname>Nicosia</surname><given-names>A</given-names></name><name><surname>Folgori</surname><given-names>A</given-names></name><name><surname>Capone</surname><given-names>S</given-names></name><name><surname>Cox</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Randomized trial of a vaccine regimen to prevent chronic HCV infection</article-title><source>The New England Journal of Medicine</source><volume>384</volume><fpage>541</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2023345</pub-id><pub-id pub-id-type="pmid">33567193</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Page-Shafer</surname><given-names>K</given-names></name><name><surname>Pappalardo</surname><given-names>BL</given-names></name><name><surname>Tobler</surname><given-names>LH</given-names></name><name><surname>Phelps</surname><given-names>BH</given-names></name><name><surname>Edlin</surname><given-names>BR</given-names></name><name><surname>Moss</surname><given-names>AR</given-names></name><name><surname>Wright</surname><given-names>TL</given-names></name><name><surname>Wright</surname><given-names>DJ</given-names></name><name><surname>O’Brien</surname><given-names>TR</given-names></name><name><surname>Caglioti</surname><given-names>S</given-names></name><name><surname>Busch</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates</article-title><source>Journal of Clinical Microbiology</source><volume>46</volume><fpage>499</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1128/JCM.01229-07</pub-id><pub-id pub-id-type="pmid">18032621</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Preston</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>IEDBTool2</data-title><version designator="swh:1:rev:065f6e76bd708918e75888ae0c06e35b11fee753">swh:1:rev:065f6e76bd708918e75888ae0c06e35b11fee753</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:655368d9eb979daa6853ba96aa16def992de500e;origin=https://github.com/PrestonLeung/IEDBTool2;visit=swh:1:snp:bcad74bfd2280461ded162a5b24a6a0152ccf08d;anchor=swh:1:rev:065f6e76bd708918e75888ae0c06e35b11fee753">https://archive.softwareheritage.org/swh:1:dir:655368d9eb979daa6853ba96aa16def992de500e;origin=https://github.com/PrestonLeung/IEDBTool2;visit=swh:1:snp:bcad74bfd2280461ded162a5b24a6a0152ccf08d;anchor=swh:1:rev:065f6e76bd708918e75888ae0c06e35b11fee753</ext-link></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quadeer</surname><given-names>AA</given-names></name><name><surname>Louie</surname><given-names>RHY</given-names></name><name><surname>McKay</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identifying immunologically-vulnerable regions of the HCV E2 glycoprotein and broadly neutralizing antibodies that target them</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2073</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09819-1</pub-id><pub-id pub-id-type="pmid">31061402</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="software"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><year iso-8601-date="2012">2012</year><data-title>R: a language and environment for statistical computing</data-title><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org">https://www.r-project.org</ext-link></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigo</surname><given-names>C</given-names></name><name><surname>Walker</surname><given-names>MR</given-names></name><name><surname>Leung</surname><given-names>P</given-names></name><name><surname>Eltahla</surname><given-names>AA</given-names></name><name><surname>Grebely</surname><given-names>J</given-names></name><name><surname>Dore</surname><given-names>GJ</given-names></name><name><surname>Applegate</surname><given-names>T</given-names></name><name><surname>Page</surname><given-names>K</given-names></name><name><surname>Dwivedi</surname><given-names>S</given-names></name><name><surname>Bruneau</surname><given-names>J</given-names></name><name><surname>Morris</surname><given-names>MD</given-names></name><name><surname>Cox</surname><given-names>AL</given-names></name><name><surname>Osburn</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>AY</given-names></name><name><surname>Schinkel</surname><given-names>J</given-names></name><name><surname>Shoukry</surname><given-names>NH</given-names></name><name><surname>Lauer</surname><given-names>GM</given-names></name><name><surname>Maher</surname><given-names>L</given-names></name><name><surname>Hellard</surname><given-names>M</given-names></name><name><surname>Prins</surname><given-names>M</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name><name><surname>Lloyd</surname><given-names>AR</given-names></name><name><surname>Bull</surname><given-names>RA</given-names></name><collab>InC Study Group</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection</article-title><source>Infection, Genetics and Evolution</source><volume>49</volume><fpage>88</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2017.01.006</pub-id><pub-id pub-id-type="pmid">28065804</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salazar-Gonzalez</surname><given-names>JF</given-names></name><name><surname>Salazar</surname><given-names>MG</given-names></name><name><surname>Keele</surname><given-names>BF</given-names></name><name><surname>Learn</surname><given-names>GH</given-names></name><name><surname>Giorgi</surname><given-names>EE</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Decker</surname><given-names>JM</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Baalwa</surname><given-names>J</given-names></name><name><surname>Kraus</surname><given-names>MH</given-names></name><name><surname>Parrish</surname><given-names>NF</given-names></name><name><surname>Shaw</surname><given-names>KS</given-names></name><name><surname>Guffey</surname><given-names>MB</given-names></name><name><surname>Bar</surname><given-names>KJ</given-names></name><name><surname>Davis</surname><given-names>KL</given-names></name><name><surname>Ochsenbauer-Jambor</surname><given-names>C</given-names></name><name><surname>Kappes</surname><given-names>JC</given-names></name><name><surname>Saag</surname><given-names>MS</given-names></name><name><surname>Cohen</surname><given-names>MS</given-names></name><name><surname>Mulenga</surname><given-names>J</given-names></name><name><surname>Derdeyn</surname><given-names>CA</given-names></name><name><surname>Allen</surname><given-names>S</given-names></name><name><surname>Hunter</surname><given-names>E</given-names></name><name><surname>Markowitz</surname><given-names>M</given-names></name><name><surname>Hraber</surname><given-names>P</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Bhattacharya</surname><given-names>T</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Korber</surname><given-names>BT</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection</article-title><source>The Journal of Experimental Medicine</source><volume>206</volume><fpage>1273</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1084/jem.20090378</pub-id><pub-id pub-id-type="pmid">19487424</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanjuán</surname><given-names>R</given-names></name><name><surname>Moya</surname><given-names>A</given-names></name><name><surname>Elena</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The distribution of fitness effects caused by single-nucleotide substitutions in an RNA virus</article-title><source>PNAS</source><volume>101</volume><fpage>8396</fpage><lpage>8401</lpage><pub-id pub-id-type="doi">10.1073/pnas.0400146101</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santantonio</surname><given-names>T</given-names></name><name><surname>Wiegand</surname><given-names>J</given-names></name><name><surname>Gerlach</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Acute hepatitis C: current status and remaining challenges</article-title><source>Journal of Hepatology</source><volume>49</volume><fpage>625</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2008.07.005</pub-id><pub-id pub-id-type="pmid">18706735</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seeff</surname><given-names>LB</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Natural history of chronic hepatitis C</article-title><source>Hepatology</source><volume>36</volume><fpage>S35</fpage><lpage>S46</lpage><pub-id pub-id-type="doi">10.1053/jhep.2002.36806</pub-id><pub-id pub-id-type="pmid">12407575</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>DB</given-names></name><name><surname>Bukh</surname><given-names>J</given-names></name><name><surname>Kuiken</surname><given-names>C</given-names></name><name><surname>Muerhoff</surname><given-names>AS</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Stapleton</surname><given-names>JT</given-names></name><name><surname>Simmonds</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource</article-title><source>Hepatology</source><volume>59</volume><fpage>318</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1002/hep.26744</pub-id><pub-id pub-id-type="pmid">24115039</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Töpfer</surname><given-names>A</given-names></name><name><surname>Zagordi</surname><given-names>O</given-names></name><name><surname>Prabhakaran</surname><given-names>S</given-names></name><name><surname>Roth</surname><given-names>V</given-names></name><name><surname>Halperin</surname><given-names>E</given-names></name><name><surname>Beerenwinkel</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Probabilistic inference of viral quasispecies subject to recombination</article-title><source>Journal of Computational Biology</source><volume>20</volume><fpage>113</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1089/cmb.2012.0232</pub-id><pub-id pub-id-type="pmid">23383997</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venner</surname><given-names>CM</given-names></name><name><surname>Nankya</surname><given-names>I</given-names></name><name><surname>Kyeyune</surname><given-names>F</given-names></name><name><surname>Demers</surname><given-names>K</given-names></name><name><surname>Kwok</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>P-L</given-names></name><name><surname>Rwambuya</surname><given-names>S</given-names></name><name><surname>Munjoma</surname><given-names>M</given-names></name><name><surname>Chipato</surname><given-names>T</given-names></name><name><surname>Byamugisha</surname><given-names>J</given-names></name><name><surname>Van Der Pol</surname><given-names>B</given-names></name><name><surname>Mugyenyi</surname><given-names>P</given-names></name><name><surname>Salata</surname><given-names>RA</given-names></name><name><surname>Morrison</surname><given-names>CS</given-names></name><name><surname>Arts</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Infecting HIV-1 subtype predicts disease progression in women of Sub-Saharan Africa</article-title><source>EBioMedicine</source><volume>13</volume><fpage>305</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2016.10.014</pub-id><pub-id pub-id-type="pmid">27751765</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>MR</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Teutsch</surname><given-names>S</given-names></name><name><surname>Betz-Stablein</surname><given-names>B</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name><name><surname>Lloyd</surname><given-names>AR</given-names></name><name><surname>Bull</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Incident hepatitis C virus genotype distribution and multiple infection in Australian prisons</article-title><source>Journal of Clinical Microbiology</source><volume>54</volume><fpage>1855</fpage><lpage>1861</lpage><pub-id pub-id-type="doi">10.1128/JCM.00287-16</pub-id><pub-id pub-id-type="pmid">27170021</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>MR</given-names></name><name><surname>Leung</surname><given-names>P</given-names></name><name><surname>Eltahla</surname><given-names>AA</given-names></name><name><surname>Underwood</surname><given-names>A</given-names></name><name><surname>Abayasingam</surname><given-names>A</given-names></name><name><surname>Brasher</surname><given-names>NA</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>B-R</given-names></name><name><surname>Maher</surname><given-names>L</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name><name><surname>Lloyd</surname><given-names>AR</given-names></name><name><surname>Bull</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>13300</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-49454-w</pub-id><pub-id pub-id-type="pmid">31527718</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>MR</given-names></name><name><surname>Eltahla</surname><given-names>AA</given-names></name><name><surname>Mina</surname><given-names>MM</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Lloyd</surname><given-names>AR</given-names></name><name><surname>Bull</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Envelope-specific IgG3 and IgG1 responses are associated with clearance of acute hepatitis C virus infection</article-title><source>Viruses</source><volume>12</volume><elocation-id>75</elocation-id><pub-id pub-id-type="doi">10.3390/v12010075</pub-id><pub-id pub-id-type="pmid">31936235</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>B</given-names></name><name><surname>Dore</surname><given-names>GJ</given-names></name><name><surname>Lloyd</surname><given-names>AR</given-names></name><name><surname>Rawlinson</surname><given-names>WD</given-names></name><name><surname>Maher</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study</article-title><source>The Medical Journal of Australia</source><volume>201</volume><fpage>326</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.5694/mja13.00153</pub-id><pub-id pub-id-type="pmid">25222455</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><source>Ggplot2: Elegant Graphics for Data Analysis</source><publisher-name>Springer</publisher-name><pub-id pub-id-type="doi">10.1007/978-3-319-24277-4</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilm</surname><given-names>A</given-names></name><name><surname>Aw</surname><given-names>PPK</given-names></name><name><surname>Bertrand</surname><given-names>D</given-names></name><name><surname>Yeo</surname><given-names>GHT</given-names></name><name><surname>Ong</surname><given-names>SH</given-names></name><name><surname>Wong</surname><given-names>CH</given-names></name><name><surname>Khor</surname><given-names>CC</given-names></name><name><surname>Petric</surname><given-names>R</given-names></name><name><surname>Hibberd</surname><given-names>ML</given-names></name><name><surname>Nagarajan</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets</article-title><source>Nucleic Acids Research</source><volume>40</volume><fpage>11189</fpage><lpage>11201</lpage><pub-id pub-id-type="doi">10.1093/nar/gks918</pub-id><pub-id pub-id-type="pmid">23066108</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zagordi</surname><given-names>O</given-names></name><name><surname>Bhattacharya</surname><given-names>A</given-names></name><name><surname>Eriksson</surname><given-names>N</given-names></name><name><surname>Beerenwinkel</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>ShoRAH: estimating the genetic diversity of a mixed sample from next-generation sequencing data</article-title><source>BMC Bioinformatics</source><volume>12</volume><elocation-id>119</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-12-119</pub-id><pub-id pub-id-type="pmid">21521499</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Quadeer</surname><given-names>AA</given-names></name><name><surname>McKay</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Evolutionary modeling reveals enhanced mutational flexibility of HCV subtype 1b compared with 1a</article-title><source>iScience</source><volume>25</volume><elocation-id>103569</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2021.103569</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Bull</surname><given-names>RA</given-names></name><name><surname>Quadeer</surname><given-names>AA</given-names></name><name><surname>McKay</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>HCV E1 influences the fitness landscape of E2 and may enhance escape from E2-specific antibodies</article-title><source>Virus Evolution</source><volume>9</volume><elocation-id>vead068</elocation-id><pub-id pub-id-type="doi">10.1093/ve/vead068</pub-id><pub-id pub-id-type="pmid">38107333</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102232.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Delgui</surname><given-names>Laura Ruth</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Consejo Nacional de Investigaciones Científicas y Técnicas</institution><country>Argentina</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>The authors examined the evolution of hepatitis C virus (HCV) in a cohort of 14 subjects with recent HCV infections. They showed that viral fitness declines as the virus mutates to escape the immune response and can rebound later in infection as HCV accumulates additional mutations. The study contributes to an <bold>important</bold> aspect of viral evolution. The combination of approaches contributes to a <bold>convincing</bold> study.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102232.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors examine CD8 T cell selective pressure in early HCV infection using. They propose that after initial CD8-T mediated loss of virus fitness, in some participants around 3 months after infection, HCV acquires compensatory mutations and improved fitness leading to virus progression.</p><p>Strengths:</p><p>Throughout the paper, the authors apply well-established approaches in studies of acute to chronic HIV infection for studies of HCV infection. This lends rigor the to the authors' work.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102232.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In this work, Walker and collaborators study the evolution of hepatitis C virus (HCV) in a cohort of 14 subjects with recent HCV infections. They focus in particular on the interplay between HCV and the immune system, including the accumulation of mutations in CD8+ T cell epitopes to evade immunity. Using a computational method to estimate the fitness effects of HCV mutations, they find that intrinsic viral fitness declines as the virus mutates to escape T cell responses. In long-term infections, they found that viral fitness can rebound later in infection as HCV accumulates additional mutations.</p><p>Strengths:</p><p>This work is especially interesting for several reasons. Individuals who developed chronic infections were followed over fairly long times and, in most cases, samples of the viral population were obtained frequently. At the same time, the authors also measured CD8+ T cell and antibody responses to infection. The analysis of HCV evolution focused not only on variation within particular CD8+ T cell epitopes, but also the surrounding proteins. Overall, this work is notable for integrating information about HCV sequence evolution, host immune responses, and computational metrics of fitness and sequence variation. The evidence presented by the authors supports the main conclusions of the paper described above.</p><p>Weaknesses:</p><p>After revision, this paper has no outstanding weaknesses. Points where further investigation is needed have been clearly identified.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102232.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Walker</surname><given-names>Melanie Rose</given-names></name><role specific-use="author">Author</role><aff><institution>UNSW Sydney</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Leung</surname><given-names>Preston</given-names></name><role specific-use="author">Author</role><aff><institution>UNSW Sydney</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Keoshkerian</surname><given-names>Elizabeth</given-names></name><role specific-use="author">Author</role><aff><institution>UNSW Sydney</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Pirozyan</surname><given-names>Mehdi R</given-names></name><role specific-use="author">Author</role><aff><institution>UNSW Sydney</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Lloyd</surname><given-names>Andrew</given-names></name><role specific-use="author">Author</role><aff><institution>The University of New South Wales</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Luciani</surname><given-names>Fabio</given-names></name><role specific-use="author">Author</role><aff><institution>UNSW Sydney</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Bull</surname><given-names>Rowena A</given-names></name><role specific-use="author">Author</role><aff><institution>UNSW Sydney</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>The authors examine CD8 T cell selective pressure in early HCV infection using. They propose that after initial CD8-T mediated loss of virus fitness, in some participants around 3 months after infection, HCV acquires compensatory mutations and improved fitness leading to virus progression.</p><p>Strengths:</p><p>Throughout the paper, the authors apply well-established approaches in studies of acute to chronic HIV infection for studies of HCV infection. This lends rigor the to the authors' work.</p><p>Weaknesses:</p><p>(1) The Discussion could be strengthened by a direct discussion of the parallels/differences in results between HIV and HCV infections in terms of T cell selection, entropy, and fitness.</p></disp-quote><p>We have added a direct discussion of the parallels/differences between HIV and HCV throughout the discussion including at lines 308 – 310 and 315 -327.</p><p>Lines 308-310: “In fact, many parallels can be drawn between HIV infections and HCV infections in the context of emerging viral species that escape T cell immune responses.”</p><p>Lines: 315-327: “One major difference between HCV and HIV infection is the event where patients infected with HCV have an approximately 25% chance to naturally clear the infection as opposed to just achieving viral control in HIV infections. Here, we probed the underlying mechanism, and questioned how the host immune response and HCV mutational landscape can allow the virus to escape the immune system. To understand this process, taking inspiration from HIV studies (24), a quantitative analysis of viral fitness relative to viral haplotypes was conducted using longitudinal samples to investigate whether a similar phenomenon was identified in HCV infections for our cohort for patients who progress to chronic infection. We observed a decrease in population average relative fitness in the period of &lt;90DPI with respect to the T/F virus in chronic subjects infected with HCV. The decrease in fitness correlated positively with IFN-γ ELISPOT responses and negatively with SE indicating that CD8+ T-cell responses drove the rapid emergence of immune escape variants, which initially reduced viral fitness. This is similarly reflected in HIV infected patients where strong CD8+ T-cell responses drove quicker emergence of immune escape variants, often accompanied by compensatory mutations (24).”</p><disp-quote content-type="editor-comment"><p>(2) In the Results, please describe the Barton model functionality and why the fitness landscape model was most applicable for studies of HCV viral diversity.</p></disp-quote><p>This has been added to the introduction section rather than Results as we feel that it is more appropriate to show why it is most applicable to HCV viral diversity in the background section of the manuscript. We write at lines 77-90:</p><p>“Barton et al.’s [23] approach to understand HIV mutational landscape resulting in immune escape had two fundamental points: (1) replicative fitness depends on the virus sequence and the requirement to consider the effect of co-occurring mutations, and (2) evolutionary dynamics (e.g. host immune pressure). Together they pave the way to predict the mutational space in which viral strains can change given the unique immune pressure exerted by individuals infected with HIV. This model fits well with the pathology of HCV infection. For instance, HIV and HCV are both RNA viruses with rapid rate of mutation. Additionally, like HIV, chronic infection is an outcome for HCV infected individuals, however, unlike HIV, there is a 25% probability that individuals infected with HCV will naturally clear the virus. Previously published studies [9] have shown that HIV also goes through a genetic bottleneck which results in the T/F virus losing dominance and replaced by a chronic subtype, identified by the immune escape mutations. The concepts in Barton’s model and its functionality to assess the fitness based on the complex interaction between viral sequence composition and host immune response is also applicable to early HCV infection.”</p><disp-quote content-type="editor-comment"><p>(3) Recognize the caveats of the HCV mapping data presented.</p></disp-quote><p>We have now recognized the caveats of the HCV mapping data at lines 354-256 “While our findings here are promising, it should be recognized that although the bioinformatics tool (iedb_tool.py) proved useful for identifying potential epitopes, there could be epitopes that are not predicted or false-positive from the output which could lead to missing real epitopes”</p><disp-quote content-type="editor-comment"><p>(4) The authors should provide more data or cite publications to support the authors' statement that HCV-specific CD8 T cell responses decline following infection.</p></disp-quote><p>We have now clarified at lines 352-353 that the decline was toward “selected epitopes that showed evidence of escape”.</p><p>Furthermore, we have cited two publications at line 352 that support our statement.</p><disp-quote content-type="editor-comment"><p>(5) Similarly, as the authors' measurements of HCV T and humoral responses were not exhaustive, the text describing the decline of T cells with the onset of humoral immunity needs caveats or more rigorous discussion with citations (Discussion lines 319-321).</p></disp-quote><p>We have now added a caveat in the discussion at lines 357-360 which reads</p><p>“In conclusion, this study provides initial insights into the evolutionary dynamics of HCV, showing that an early, robust CD8+ T-cell response without nAbs strongly selects against the T/F virus, enabling it to escape and establish chronic infection. However, these findings are preliminary and not exhaustive, warranting further investigation to fully understand these dynamics. “</p><disp-quote content-type="editor-comment"><p>(6) What role does antigen drive play in these data -for both T can and antibody induction?</p></disp-quote><p>It is possible that HLA-adapted mutations could limit CD8 T cell induction if the HLAs were matched between transmission pairs, as has been shown previously for HIV (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.ppat.1008177">https://doi.org/10.1371/journal.ppat.1008177</ext-link>) with some data for HCV (<ext-link ext-link-type="uri" xlink:href="https://journals.asm.org/doi/10.1128/jvi.00912-06">https://journals.asm.org/doi/10.1128/jvi.00912-06</ext-link>). However, we apologise as we are not entirely sure that this is what the reviewer is asking for in this instance.</p><disp-quote content-type="editor-comment"><p>(7) Figure 3 - are the X and Y axes wrongly labelled? The Divergent ranges of population fitness do not make sense.</p></disp-quote><p>Our apologies, there was an error with the plot in Figure 3 and the X and Y axis were wrongly labelled. This has now been resolved.</p><disp-quote content-type="editor-comment"><p>(8) Figure S3 - is the green line, average virus fitness?</p></disp-quote><p>This has now been clarified in Figure S3.</p><disp-quote content-type="editor-comment"><p>(9) Use the term antibody epitopes, not B cell epitopes.</p></disp-quote><p>We now use the term antibody epitopes throughout the manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>Recommendations for improving the writing and presentation:</p><p>(1) Introduction:</p><p>Line 52: 'carry mutations B/T cell epitopes'. Two points</p><p>i) These are antibody epitopes (and antibody selection) not B cell epitopes</p></disp-quote><p>We have corrected this sentence at line 55 which now reads: “carry mutations within epitopes targeted by B cells and CD8+ T cells”.</p><disp-quote content-type="editor-comment"><p>ii) To avoid confusion, add text that mutations were generated following selection in the donor.</p></disp-quote><p>For HCV, it is unclear if mutations are generated following selection or have been occurring in low frequencies outside detection range. Only when selection by host immune pressure arises do the potentially low-frequency variants become dominant. However, we do acknowledge it is potentially misleading to only mention new variants replacing the transmitted/founder population. We have modified the sentence at line 52 to read:</p><p>“At this stage either an existing variant that was occurring in low-frequency outside detection range or an existing variant with novel mutations generated following immune selection is observed in those who progress to chronic infection”</p><disp-quote content-type="editor-comment"><p>- Lines 51-56: Human studies of escape and progression are associative, not causative as implied.</p></disp-quote><p>Correct, evidence suggesting that escape and progression are currently associative. We have now corrected these lines to no longer suggest causation.</p><disp-quote content-type="editor-comment"><p>- Line 65: Suggest you clarify your meaning of 'easier'?</p></disp-quote><p>This sentence, now at line 72, has been modified to: “subtype 1b viruses have a higher probability to evade immune responses”</p><disp-quote content-type="editor-comment"><p>(2) Results:</p><p>- Line 147: Barton model (ref'd in Intro) is directly referred to here but not referenced.</p></disp-quote><p>The reference has been added.</p><disp-quote content-type="editor-comment"><p>- The authors should cite previous HIV literature describing associations between the rate of escape and Shannon Entropy e.g. the interaction between immunodominance, entropy, and rate of escape in acute HIV infection was described in Liu et al JCI 2013 but is not cited.</p></disp-quote><p>We have now cited previous HIV research at line 147-151, adding Liu et al:</p><p>“Additionally, the interaction between immunodominance, entropy, and escape rate in acute HIV infection has been described, where immunodominance during acute infection was the most significant factor influencing CD8+ T cell pressure, with higher immunodominance linked to faster escape (27). In contrast, lower epitope entropy slowed escape, and together, immunodominance and entropy explained half of the variability in escape timing (27).”</p><disp-quote content-type="editor-comment"><p>- Line 319: The authors suggest that HCV-specific CD8 T cell response declines following early infection. On what are they basing this statement? The authors show their measured T cell responses decline but their approach uses selected epitopes and they are therefore unable to assess total HCV T cell response in participants (Where there is no escape, are T cell magnitudes maintained or do they still decline?). Can the authors cite other studies to support their statement?</p></disp-quote><p>We have now clarified that the decline was toward “selected epitopes that showed evidence of escape”. Furthermore, we also cite two studies to support our findings.</p><disp-quote content-type="editor-comment"><p>- Throughout the authors talk in terms of CD8 T cells but the ELISpot detects both CD4 and CD8 T cell responses. I suggest the authors be more explicit that their peptide design (9-10mers) is strongly biased to only the detection of CD8 T cells.</p></disp-quote><p>To make this clearer and more explicit we have now added to the methods section at line 433-435:</p><p>“While the ELISpot assay detects responses from both CD4 and CD8 T cells, our peptide design (9-10mers) is strongly biased toward CD8 T-cell detection. We have therefore interpreted ELISpot responses primarily in terms of CD8 T-cell activity.”</p><disp-quote content-type="editor-comment"><list list-type="bullet" id="list1"><list-item><p>The points made in lines 307-321 could be more succinct</p></list-item></list></disp-quote><p>We have now edited the discussion (lines 307 – 321) to make the points more succinct (now lines 307-323).</p><disp-quote content-type="editor-comment"><p>Minor corrections to text, figures:</p><p>- Figure 2: suggest making the Key bigger and more obvious.</p></disp-quote><p>We have now made the key bigger and more obvious</p><disp-quote content-type="editor-comment"><p>- Figure 3 A &amp; D....is there an error on the X-axis...are you really reporting ELISpot data of &lt; 1 spot/10^6? Perhaps the X and Y axes are wrongly labelled?</p></disp-quote><p>Our apologies, there was an error with the plot in Figure 3 and the X and Y axis were wrongly labelled. This has now been resolved.</p><disp-quote content-type="editor-comment"><p>- Figure 5: As this is PBMC, remove CD8 from the description of ELISpot.</p></disp-quote><p>We have now removed CD8 from the description of ELISpot in both Figure 5 and Figure S3</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>In this work, Walker and collaborators study the evolution of hepatitis C virus (HCV) in a cohort of 14 subjects with recent HCV infections. They focus in particular on the interplay between HCV and the immune system, including the accumulation of mutations in CD8+ T cell epitopes to evade immunity. Using a computational method to estimate the fitness effects of HCV mutations, they find that viral fitness declines as the virus mutates to escape T-cell responses. In long-term infections, they found that viral fitness can rebound later in infection as HCV accumulates additional mutations.</p><p>Strengths:</p><p>This work is especially interesting for several reasons. Individuals who developed chronic infections were followed over fairly long times and, in most cases, samples of the viral population were obtained frequently. At the same time, the authors also measured CD8+ T cell and antibody responses to infection. The analysis of HCV evolution focused not only on variation within particular CD8+ T cell epitopes but also on the surrounding proteins. Overall, this work is notable for integrating information about HCV sequence evolution, host immune responses, and computational metrics of fitness and sequence variation. The evidence presented by the authors supports the main conclusions of the paper described above.</p><p>Weaknesses:</p><p>One notable weakness of the present version of the manuscript is a lack of clarity in the description of the method of fitness estimation. In the previous studies of HIV and HCV cited by the authors, fitness models were derived by fitting the model (equation between lines 435 and 436) to viral sequence data collected from many different individuals. In the section &quot;Estimating survival fitness of viral variants,&quot; it is not entirely clear if Walker and collaborators have used the same approach (i.e., fitting the model to viral sequences from many individuals), or whether they have used the sequence data from each individual to produce models that are specific to each subject. If it is the former, then the authors should describe where these sequences were obtained and the statistics of the data.</p><p>If the fitness models were inferred based on the data from each subject, then more explanation is needed. In prior work, the use of these models to estimate fitness was justified by arguing that sequence variants common to many individuals are likely to be well-tolerated by the virus, while ones that are rare are likely to have high fitness costs. This justification is less clear for sequence variation within a single individual, where the viral population has had much less time to &quot;explore&quot; the sequence landscape. Nonetheless, there is precedent for this kind of analysis (see, e.g., Asti et al., PLoS Comput Biol 2016). If the authors took this approach, then this point should be discussed clearly and contrasted with the prior HIV and HCV studies.</p></disp-quote><p>We thank the reviewer for pointing out the weakness in our explanation and description of the fitness model. The model has been generated using publicly released viral sequences and this has been described in a previous publication by Hart et al. 2015. T/F virus from each of the subjects chronically infected with HCV in our cohort were given to the model by Hart et al. to estimate the initial viral fitness of the T/F variant. Subsequent time points of each subject containing the subvariants of the viral population were also estimated using the same model (each subtype). For each subject, these subvariant viral fitness values were divided by the fitness value of the initial T/F virus (hence relative fitness of the earliest time points with no mutations in the epitope regions were a value of 1.000). All other fitness values are therefore relative fitness to the T/F variant.</p><p>We have further clarified this point in the methods section “Estimating survival fitness of viral variant” to better describe how the data of the model was sourced (Lines 465-499).</p><p>To add to the reviewer’s point, we agree that sequence variants common to many individuals are likely to be well-tolerated by the virus and this event was observed in our findings as our data suggested that immune escape variants tended to revert to variants that were closer the global consensus strain. Our previous publications have indicated that T/F viruses during transmission were variants that were “fit” for transmission between hosts, especially in cases where the donor was a chronic progressor, a single T/F is often observed. Progression to immune escape and adaptation to chronic infection in the new host has an in-between process of genetic expansion via replication followed by a bottleneck event under immune pressure where overall fitness (overall survivability including replication and exploring immune escape pathways) can change. Under this assumption we questioned whether the observation reported in HIV studies (i.e. mutation landscapes that allow HIV adaptation to host) also happens in HCV infections. Furthermore, cohort used in this study is a rare cohort where patients were tracked from uninfected, to HCV RNA+, to seroconversion and finally either clearing the virus or progression to chronic infection. Thus, it is of importance to understand the difference between clearance and chronic progression.</p><disp-quote content-type="editor-comment"><p>Another important point for clarification is the definition of fitness. In the abstract, the authors note that multiple studies have shown that viral escape variants can have reduced fitness, &quot;diminishing the survival of the viral strain within the host, and the capacity of the variant to survive future transmission events.&quot; It would be helpful to distinguish between this notion of fitness, which has sometimes been referred to as &quot;intrinsic fitness,&quot; and a definition of fitness that describes the success of different viral strains within a particular individual, including the potential benefits of immune escape. In many cases, escape variants displace variants without escape mutations, showing that their ability to survive and replicate within a specific host is actually improved relative to variants without escape mutations. However, escape mutations may harm the virus's ability to replicate in other contexts. Given the major role that fitness plays in this paper, it would be helpful for readers to clearly discuss how fitness is defined and to distinguish between fitness within and between hosts (potentially also mentioning relevant concepts such as &quot;transmission fitness,&quot; i.e., the relative ability of a particular variant to establish new infections).</p></disp-quote><p>Thank you for pointing out the weakness of our definition of fitness. We have now clarified this at multiple sections of the paper: In the abstract at lines 18-21 and in the introduction at lines 64-69.</p><p>These read:</p><p>Lines 18-21: “However, this generic definition can be further divided into two categories where intrinsic fitness describes the viral fitness without the influence of any immune pressure and effective fitness considers both intrinsic fitness with the influence of host immune pressure.”</p><p>Lines 64-69: “This generic definition of fitness can be further divided into intrinsic fitness (also referred to as replicative fitness), where the fitness of sequence composition of the variant is estimated without the influence of host immune pressure. On the other hand, effective fitness (from here on referred to as viral fitness) considers fundamental intrinsic fitness with host immune pressure acting as a selective force to direct mutational landscape (19)[REF], which subsequently influences future transmission events as it dictates which subvariants remain in the quasispecies.”</p><disp-quote content-type="editor-comment"><p>One concern about the analysis is in the test of Shannon entropy as a way to quantify the rate of escape. The authors describe computing the entropy at multiple time points preceding the time when escape mutations were observed to fix in a particular epitope. Which entropy values were used to compare with the escape rate? If just the time point directly preceding the fixation of escape mutations, could escape mutations have already been present in the population at that time, increasing the entropy and thus drawing an association with the rate of escape? It would also be helpful for readers to include a definition of entropy in the methods, in addition to a reference to prior work. For example, it is not clear what is being averaged when &quot;average SE&quot; is described.</p></disp-quote><p>We thank the reviewer to point out the ambiguity in describing average SE. This has been rectified by adding more information in the methods section (Lines 397 to 400):</p><p>“Briefly, SE was calculated using the frequency of occurrence of SNPs based on per codon position, this was further normalized by the length of the number of codons in the sequence which made up respective protein. An average SE value was calculated for each time point in each protein region for all subjects until the fixation event.”</p><p>To answer the reviewer’s question, we computed entropy at multiple time points preceding the observation in the escape mutation. The escape rate was calculated for the epitopes targeted by immune response. We compared the average SE based on change of each codon position and then normalised by protein length, where the region contained the epitope and the time it took to reach fixation. We observed that if the protein region had a higher rate of variation (i.e. higher average SE) then we also see a quicker emergence of an immune escape epitope. Since we took SE from the very first time point and all subsequent time points until fixation, we do not think that escape mutations already been present at the population would alter the findings of the association with rate of escape. Especially, these escape mutations were rarely observed at early time points. It is likely that due to host immune pressure that the escape variant could be observed, the SE therefore suggest the liberty of exploration in the mutation landscape. If the region was highly restrictive where any mutations would result in a failed variant, then we should observe relatively lower values of average SE. In other words, the higher variability that is allowed in the region, the greater the probability that it will find a solution to achieve immune escape.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>In addition to the main points above, there are a few minor comments and suggestions about the presentation of the data.</p><p>(1) It's not clear how, precisely, the model-based fitness has been calculated and normalized. It would be helpful for the authors to describe this explicitly. Especially in Figure 3, the plotted fitness values lie in dramatically different ranges, which should be explained (maybe this is just an error with the plot?).</p></disp-quote><p>We have now clarified how the model-based fitness has been calculated and normalized in the method section “Estimating survival fitness of viral variants” at line 465-472.</p><p>“The model used for estimating viral fitness has been previously described by Hart et al. (19). Briefly, the original approach used HCV subtype 1a sequences to generate the model for the NS5B protein region. To update the model for other regions (NS3 and NS2) as well as other HCV subtypes in this study, subtype 1b and subtype 3a sequences were extracted from the Los Almos National Laboratory HCV database. An intrinsic fitness model was first generated for each subtype for NS5B, NS3 and NS2 region of the HCV polyprotein. Then using, longitudinally sequenced data from patients chronically infected with HCV as well as clinically documented immune escape to describe high viral fitness variants, we generated estimates of the viral fitness for subjects chronically infected with HCV in our cohort.”</p><p>Our apologies, there was an error with the plot in Figure 3. This has now been resolved.</p><disp-quote content-type="editor-comment"><p>(2) In different plots, the authors show every pairwise comparison of ELISPOT values, population fitness, average SE, and rate of escape. It may be helpful to make one large matrix of plots that shows all of these pairwise comparisons at the same time. This could make it clear how all the variables are associated with one another. To be clear, this is a suggestion that the authors can consider at their discretion.</p></disp-quote><p>Thank you for the suggestion to create a matrix of plots for pairwise comparisons. While this approach could indeed clarify variable associations, implementing it is outside the scope of this project. We appreciate the idea and may consider it in future studies as we continue to expand on this work.</p></body></sub-article></article>